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Summary 
SUMMARY 
Defective apoptosis represents one of the major causative factors in the development and 
progression of cancer. The ability of tumour cells to evade engagement of apoptosis can 
play a significant role in their resistance to conventional therapeutic regimens. In the last 
few years, preclinical and clinical studies have indicated ceramide and the enzymes of its 
metabolism, in particular Acid Sphingomyelinase (A-SMase) which hydrolyzes 
sphingomyelin to ceramide and phosphocoline, as key players in tumour 
physiopathology. Different cancers have been shown to have reduced ceramide levels 
and, of interest, in our previous work we showed that A-SMase down-regulation was a 
key event in melanoma progression. This event is crucial for the tumours to become more 
aggressive, but the mechanisms responsible of it haven’t been investigated yet. 
Taking into account that there is a complex crosstalk between tumour cells and its 
immunological microenvironment, in this work we first investigated its possible role in 
A-SMase downregulation in a melanoma model.  
To this purpose we performed in vivo and in vitro experiments which led us to identify 
tumour associate macrophages (TAM) as possible responsible of A-SMase 
downregulation through the Ap2-α transcription factor. Moreover, we demonstrated that 
these molecular changes in tumour cells give, in turn, pro-tumoural and 
immunosuppressive features to the surrounding microenvironment, with the recruitment 
of Myeloid-derived suppressor (MDSCs) cells and Regulatory T lymphocytes (TREGS). 
From these and our previous data, we clearly showed that the ability to create this 
immunosuppression together with the acquisition of a more aggressive phenotype, both 
depend on the naturally occurring A-SMase decrease in melanoma cells during tumour 
progression. 
The broad role of A-SMase in tumour pathogenesis we identified, indicates that the 
enzyme is at the crossroad of key pathways in tumourigenesis. This aspects has clear 
potential in therapeutic perspective in which A-SMase overexpression or administration 
might be consider as an useful adjuvant for cancer therapy. 
Here we demonstrated for the first time that restoring A-SMase expression in melanoma 
cells not only reduces tumour growth and immunosuppression, but moreover accounts for 




tumour microenvironment, such as Dendritic cells (DCs) and CD4+ and CD8+ T 
lymphocytes. 
In conclusion our results reveal the central role of A-SMase expressed by melanoma cells 
in orchestrating the cross-talk with the surrounding microenvironment. These interactions 
are crucial for tumour fate, lying on its rejection or progression. Our observation that A-
SMase overexpression “educate” tumour microenvironment against cancer cells, further 




Chapter 1: Tumour Microenvironment 
The tumour microenvironment is composed by several important components including 
the tumour parenchyma cells, mesenchymal cells, fibroblasts, blood and lymph vessels, as 
well as tumour infiltrating immune cells, chemokines, and cytokines (Weber and Kuo 
2012).These many and varied constituents fulfill the definition of a complex system, 
whereby the interactions between the components are multiscale, multilevel,  and consist 
of nonlinear dynamics (Oltvai and Barabasi 2002). Each of these components can make 
important contributions to tumour development and progression. 
1.1 Composition 
Figure 1: The primary tumour microenvironment(Joyce and Pollard 2009) 
Cancer cells in primary tumours are surrounded by a complex microenvironment comprising numerous 
cells including endothelial cells of the blood and lymphatic circulation, stromal fibroblasts and a variety of 
bone marrow-derived cells (BMDCs) including macrophages, myeloid-derived suppressor cells (MDSCs), 




1.2 Non immune components 
Among the non immune components, tumour associated fibroblasts are responsible for 
the formation and remodelling of the extracellular matrix and constitute a source of 
factors which promote the growth of carcinoma cells (Bhowmick, Neilson et al. 2004). 
The formation of new vessels is critical for tumour progression as the mass grows bigger 
(Carmeliet and Jain 2000), while existing blood and lymphatic vessels may act as routes 
for local invasion and distant metastasis (Sleeman and Thiele 2009; Weis and Cheresh 
2011). Many studies have shown that the density of blood vessels and the production of 
factors that stimulate blood vessel formation, including vascular endothelial growth 
factor(VEGF), platelet-derived growth factor (PDGF), and matrix metalloproteinases 
(MMPs), contribute to the spread of tumour cells and predict poor patient survival (Weis 
and Cheresh 2011). Other host cell lineages including mesenchymal stem cells not only 
form new carcinoma cells, but are also able to differentiate into the various cell types 
required to drive angiogenesis during cancer progression (Mohseny and Hogendoorn 
2011). 
1.3 Immune components 
The immune components of tumour microenvironment have gained attention in the last 
decades for their critical role in tumourigenesis and tumour control. Tumour-infiltrating 
immune cells including myeloid-derived suppressor cells (MDSC), tumour-associated 
macrophages (TAM), and cytotoxic lymphocytes are critical determinants of cancer 
outcomes. Several studies have shown that increased densities of MDSC and TAM 
promote tumour progression via multiple suppressive mechanisms (Mantovani, Schioppa 
et al. 2006; Ostrand-Rosenberg and Sinha 2009). In contrast, the presence of cytotoxic 
lymphocytes within the tumour microenvironment is associated with a good prognosis in 
many cancers (Pages, Galon et al. 2010; Tosolini, Kirilovsky et al. 2011; Chew, Chen et 
al. 2012). 
Other immune components of the tumour microenvironment, including chemokines and 
cytokines, may also alter the local balance of pro-regulatory and anti-tumourimmune 
responses (Wilson and Balkwill 2002; Balkwill 2004). Danger signals such as heat shock 
proteins, nucleic acids, and HMGB1 released from transformed, dying, or dead tumour 
cells in the microenvironment tare sensed by innate immunity components such as the 
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toll-like receptors (TLRs) and can activate antitumour immune responses (Matzinger 
2002; Sims, Rowe et al. 2010). 
Macrophages. 
Macrophages represent a significant portion of the tumour mass, and they certainly 
operate as fundamental actors in various types of solid cancers (Hao, Lu et al. 2012) 
facilitating tumour progression via both immunological and non immunological 
mechanisms. They form a continuous spectrum of cells that range in phenotype from M1-
like or classically activated macrophages to M2-like or alternatively-activated 
macrophages (Mantovani, Sica et al. 2009). M1-like macrophages are typically activated 
by IFNγ, and lipopolysaccharide (LPS), and are characterised by their high expression of 
IL-12 and low expression of IL-10. This cytokine profile promotes the development of a 
type 1 T cell response which facilitates anti-tumour immunity. In addition, M1-like 
macrophages can be tumouricidal. In contrast, M2-like macrophages are activated byIL-4, 
IL-13, IL-10, and glucocorticoid hormones, produce high levels of IL-10 and low levels 
of IL-12, and promote tumour progression. Macrophages phenotype is driven by their 
local tissue microenvironment and the tumour microenvironment has been shown to 
strongly polarise macrophages towards an M2-like phenotype, giving rise to so-called 
“tumour associated macrophages” (TAMs) (Ostrand-Rosenberg, Sinha et al. 2012), even 
if recent studies have identified up to seven phenotypically different macrophage 
subpopulations within tumours, demonstrating the complexity of this cell population 
(Movahedi, Laoui et al. 2010). Analysing TAM phenotype from a molecular point of 
view, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and 
Hypoxia-inducible factor 1-alpha(HIF-1) have been identified as master regulators of 
TAM's transcriptional programs and, at the same time, as central regulators of tumour 
progression and metastasis (Sica and Bronte 2007).  
TAM products can influence many aspects of tumour growth and progression 
(Mantovani, Allavena et al. 2008). In particular, they can regulate senescence; interact 
with and contribute to extracellular matrix remodelling; promote cancer cell proliferation, 
invasion and metastasis (Lin, Li et al. 2006); sustain angiogenesis and lymphangiogenesis 
(Lin, Li et al. 2006; Clear, Lee et al. 2010). TAMs express low levels of the major 
histocompatibility complex class II and reduced antimicrobial and tumouricidal activity. 
Finally, they suppress anti-tumoural adaptive immunity. 
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TAMs produce enzymes and proteases, which regulate the digestion of components of the 
extracellular matrix (ECM), such as matrix metalloproteases (MMPs), plasmin, 
urokinase-type plasminogen activator (uPA) and the uPA receptor (Nagakawa, Aoki et al. 
2002). MMP expression has been implicated in tumour progression through enhancing 
angiogenesis, tumour invasion and metastasis (Naylor, Stamp et al. 1994; Wang, So et al. 
2005). TAMs have been reported to correlate with the metastatic potential of a variety of 
human cancers (Lin, Li et al. 2011; Wei, Fang et al. 2012) and they have also been shown 
to be a major source of MMP-9 (Wang, Zhang et al. 2011). 
Moreover, TAMs have been shown to promote angiogenesis and lymphangiogenesis by 
releasing proangiogenic growth factors such as TGF-β, VEGF-A, VEGF-C, EGF, 
thymidine phosporylase (TP) and chemokines, such as CCL2/MCP-1 and CXCL8/IL-8 
(Hotchkiss, Ashton et al. 2003; Lin, Li et al. 2006; Murdoch, Muthana et al. 2008; 
Granata, Frattini et al. 2010; Schmidt and Carmeliet 2010) favouring subsequent 
dissemination of cancer cells In this perspective, macrophages act as “bridge cells” or 
“cellular chaperones” that guide the fusion of endothelial tip cells (vascular anastomosis) 
and facilitate vascular sprouting (Fantin, Vieira et al. 2010; Schmidt and Carmeliet 2010). 
An additional feature of TAMs consists in their ability to suppress the adaptive immune 
response through their poor antigen-presenting activity and inhibition of T cell 
proliferation (Sica, Schioppa et al. 2006). Tumour-specific microenvironment can alter 
the mechanisms by which TAMs can exert their immunosuppressive functions. For 
instance, in murine models of breast and lung tumours, CD8+ T cell suppression is 
dependent, at least in part, on TAM metabolic activities via arginase-1 (ARG-1) or 
inducible Nitric Oxide Synthase (i-NOS) (Doedens, Stockmann et al. 2010; Movahedi, 
Laoui et al. 2010). In contrast, in human tumours, TAM-mediated CD8+ T cell 
suppression occurs regardless of l-arginine metabolism (Kryczek, Zou et al. 2006), but it 
depends on B7-H1 in hepatocellular carcinoma (Kuang, Zhao et al. 2009) and B7-H4 in 
ovarian cancer (Kryczek, Zou et al. 2006).  
In spite of several evidences on the pro-tumoural role of TAMs in several tumours, there 
is evidence pointing in the opposite direction. In large B-cell lymphoma patients, 
Hasselblom et al. did not find any statistically significant correlation between the number 
of CD68+ cells and any clinical aspect, including progression-free survival and overall 
survival. In high-grade osteosarcoma patients (Hasselblom, Hansson et al. 2008), it has 
been found a statistically significant correlation between CD68+ cells and better survival 
(Buddingh, Kuijjer et al. 2011). In colorectal cancer (CRC), the role of TAM in tumour 
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progression seems to be controversial. Indeed, even if some studies indicated a role of 
TAMs in CRC progression, evidences indicate a strong anti-tumoural activity of TAMs 
and their association with improved disease-free survival (Forssell, Oberg et al. 2007). 
T lymphocytes. 
Both preclinical and clinical studies suggest a strict correlation between the presence of 
tumour-infiltrating lymphocytes (TILs) with a favourable prognosis in a wide number of 
solid tumours (Galon, Costes et al. 2006; Fridman, Pages et al. 2012; Senovilla, Vacchelli 
et al. 2012), although not all lymphocyte types are endowed with anti-tumour activity 
(Vesely, Kershaw et al. 2011). CTL play a relevant role in the process of tumour 
rejection. They are defined as CD8+T cells producing massive amounts of IFN-γ and 
other molecules necessary for their cytotoxic activity, such as granzyme B and perforin. 
The key role of CTL both in immune surveillance against rising malignancies and in 
contrasting the metastatic expansion has been demonstrated in mouse models exploiting 
UV-induced skin cancers (Ward, Koeppen et al. 1990), chemically induced papilloma 
(Yusuf, Nasti et al. 2008), and in the ret oncogene transgenic model of spontaneous 
melanoma (Eyles, Puaux et al. 2010). High frequencies of circulating CD8+T 
lymphocytes were detected in patients with metastatic melanoma, specific for Melan-
A/MART-1, MAGE-10, and Ny-Eso-1, and CTL have also been found infiltrating 
melanoma metastases (Clark, Elder et al. 1989; Clemente, Mihm et al. 1996; van Houdt, 
Sluijter et al. 2008; Fuertes, Kacha et al. 2011). On this basis, adoptive transfer of CTL is 
therapeutically effective for mouse tumour models, although, unfortounately ,to a minor 
extent for cancer patients (Mempel and Bauer 2009). These T cells, attracted by 
chemotactic stimuli secreted by the tumour mass, acquire the ability to migrate toward it. 
CTL do not require integrin to interact with neoplastic cells and are endowed with the 
ability to shift between components of tumour mass by means of ameboid locomotion 
(Weigelin, Krause et al. 2011). Time-lapse microscopy in a mouse melanoma model 
illustrated that melanoma-specific CTL effectively traffic to the melanoma site, where 
they engage contact with the B16-F10 cells via TCR/MHC-peptide interactions 
(Weigelin, Krause et al. 2011). Subsequently, tumour cells undergo apoptotic cell death 
induced by cytotoxic activity of CTL. These forming apoptotic bodies are made available 
for tumour-infiltrating dendritic cells (DC) that are thus allowed to sustain the systemic 
tumour-specific immune surveillance by migrating to tumour-draining lymph nodes and 
other distant lymphoid organs, such as spleen, in order to present the processed peptides 
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to naïve T cells. Moreover, it is also widely documented that the presence of TILs, 
including CTLs, is correlated with a favourable prognosis for several types of cancers, 
such as colon, breast, lung, ovarian, and oesophagus cancer, just to cite a few (Naito, 
Saito et al. 1998; Schumacher, Haensch et al. 2001; Zhang, Conejo-Garcia et al. 2003; 
Sato, Olson et al. 2005; Alexe, Dalgin et al. 2007; Al-Shibli, Donnem et al. 2008; 
Fridman, Pages et al. 2012). 
The killing efficiency of target tumour cells by CTL is dependent on several factors, such 
as the cytokine/chemokine patterns produced by the tumour microenvironment, the 
molecular plasticity of tumour cells to evade CTL-induced killing and the strength of 
TCR/MHC-peptide interactions. In this regard, melanoma cells have been shown to 
down-regulate the MHC-I surface expression, thus bypassing the interaction with CTL 
via TCR (Mempel and Bauer 2009). Of importance, it has been demonstrated that 
induction of co-stimulatory molecule expression in human melanoma cell surface led to 
stimulation of CTL activity by Natural killer (NK) cells (Tarazona, Casado et al. 2004). 
On the other hand, a significant fraction of TILs is composed by the regulatory T (TREG) 
cells, endowed with potent suppressive activity that counteract anti-tumour responses and 
favour tumour escape and progression. TREG cells were reported to infiltrate a wide range 
of mouse and human tumours, such as melanoma, lung adenocarcinoma, breast cancer, 
and gastrointestinal tumours (Quezada, Peggs et al. 2011; Wang, Ma et al. 2012). 
Elevated frequencies of TRE cells in peripheral blood and at the tumour site of cancer 
patients correlate with poor prognosis and reduced survival. However the mechanisms 
driving TREG cell expansion, accumulation, and migration to the tumour site are currently 
unknown. It is likely, that factors relevant within the tumour microenvironment, such as 
the presence of TGF-β and low antigen stimulation, may play a role in the induction of 
TREG cells in vivo (Quezada, Peggs et al. 2011). Through the secretion of inhibitory 
cytokines and the expression of surface markers, TREG cells inhibit the effector function of 
most immune cells, including T and B cells, DC, macrophages, and NK cells(Wang, Ma 
et al. 2012). FoxP3+ TREG cells within tumour burden express elevated levels of multiple 
suppressive receptors such as programmed cell death protein 1(PD-1), Cytotoxic T-
Lymphocyte Antigen 4 (CTLA-4), T cell membrane protein 3 (TIM-3), Lymphocyte-
activation gene 3 (LAG-3), and Glucocorticoid-induced TNFR family related gene 
(GITR) (Sakuishi, Apetoh et al. 2010; Park, Kusnadi et al. 2012). The identification of 
these receptors has gained interest for the development of targeted anti-tumour strategies 
aimed at selectively depleting TREG cells at the tumour site (Menetrier-Caux, Curiel et al. 
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2012; Menetrier-Caux, Faget et al. 2012; Wang, Ma et al. 2012). For example, 
simultaneous blockade of CTLA-4 and PD-1 was shown to reduce the frequencies of 
TREG cells and to increase the numbers of effector TILs in mice bearing established B16-
F10 melanoma, improving the efficacy of tumour vaccines (Curran, Montalvo et al. 
2010). Similar encouraging results have been obtained with melanoma patients, 
suggesting that approaches aimed at combining TREG cell depletion-based immunotherapy 
with current tumour treatment protocols may be promising therapeutic strategies in 
clinical oncology (Hodi, O'Day et al. 2010). However, since PD-1 and CTLA-4 are not 
uniquely expressed by TREG cells, these results may be attributable to the blockade or re-
activation of other T cell subsets (Badoual, Hans et al. 2013). In some cases TREG cells 
may also contrast tumour progression. Indeed, TREG lymphocyte infiltration has been 
associated with favourable prognosis in several types of solid cancers, such as ovarian, 
bladder, head/neck, and colorectal tumours (Badoual, Hans et al. 2009; Fridman, Pages et 
al. 2012). The mechanisms by which TREG cells exert opposite function, depending on the 
tumour type, are still under investigation, although it is plausible to hypothesise that the 
phenotypical uniqueness of each cancer microenvironment may elicit the recruitment of 
different TREG cell subsets (Fridman, Pages et al. 2012). 
Dendritic cells. 
The major function of dendritic cells (DC) is to process and present antigen for the 
activation of CD4+ and CD8+ T cells. Endocytosis of antigen by immature DC drives DC 
maturation and the subsequent presentation of antigen to T cells. However, the tumour 
microenvironment systemically perturbs this process by increase in the accumulation of 
immature DC and decreasing DC maturation (Gabrilovich 2004). As a result, DC fail to 
activate tumour-reactive T cells and/or become tolerogenic. Defective dendritic cell 
function has been found in many patients with a variety of cancers, as well as inmost 
mice with transplanted or spontaneous tumours (Pinzon-Charry, Maxwell et al. 2005). 
Multiple conditions and factors within the tumour microenvironment, including hypoxia, 
lactic acid build-up, and adenosine accumulation, cause DC abnormalities (Gabrilovich, 
Ostrand-Rosenberg et al. 2012). In this respect, DC may be viewed as a double-edged 
sword at the tumour site affecting either positively or negatively the anti-tumour 
response, depending on the composition of the tumour microenvironment (Schiavoni, 
Gabriele et al. 2013). 
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As explained above, tumour-infiltrating DC (TIDC) are present in different types of solid 
cancers, but the largest number of TIDC has been found in melanoma (Furumoto, Soares 
et al. 2004). These TIDC are composed by myeloid and to a lesser extent plasmacytoid 
DC (Mattei, Schiavoni et al. 2012). The latter display an immature phenotype in situ, but 
retain the ability to mature into fully competent APC following dissociation from the 
tumour bulk, without the need of cytokine or bacterial product exposure (Preynat-Seauve, 
Schuler et al. 2006). In this regard, dying tumour cells are thought to provide maturation 
signals. Therefore, DC spontaneously infiltrate melanoma and other types of solid 
cancers, and are potentially endowed with the capability to process a soluble tumour-
associated antigen (Preynat-Seauve, Schuler et al. 2006). These TIDC then migrate 
toward draining lymph nodes in order to activate both naïve CD4+and CD8+T 
lymphocytes (Fuertes, Kacha et al. 2011; Gerlini, Di Gennaro et al. 2012; Gerlini, Sestini 
et al. 2013). Therefore, newly generated cytotoxic CD8+T cells may further contribute to 
tumour rejection by migrating toward the tumour site. The extent of tumour infiltration by 
mature DC has been often correlated with favourable prognosis in a wide array of clinical 
cancers (Cox, North et al. 2005; Ladanyi, Kiss et al. 2007; Park, Lee et al. 2012). In a 
mouse model of melanoma, it was recently shown that host immunodeficiency results in 
poor tumour infiltration by effector immune cells, such as T cells and DC, and closely 
associates with melanoma progression (Mattei, Schiavoni et al. 2012). In this model, 
melanoma phenotype was shown to be shaped directly by cells of the immune system 
through release of soluble factors within the tumour microenvironment (Businaro, De 
Ninno et al. 2013). 
Natural Killer cells. 
NK cells are large granular lymphocytes acting by their cytotoxic capacity and massive 
cytokine production. Human NK cells share with macrophages the surface expression of 
CD16 (FcyRIII), but are diversified from them by expression of CD7, CD56, and CD57 
(Milush, Long et al. 2009; Yasuda, Aritaka et al. 2011; Senovilla, Vacchelli et al. 2012) 
and by mechanisms of pathogen killing. Indeed, whereas macrophages kill target cells by 
phagocytosis, NK cells mediate target cell lysis by secretion of perforin- and granzyme B-
containing granules (Pardo, Aguilo et al. 2009; Afonina, Cullen et al. 2010). A recent 
report demonstrated that NK cells are endowed with a potent ability to secrete calcium 
ions, and that this function allow these cells to increase their killing ability (Schwarz, Qu 
et al. 2013). For their killing activity, NK cells cover an important role in immune 
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responses against tumours. Another interesting function of NK cells is the so called “DC 
editing.” This term specifies the ability of activated NK cells to interact with autologous 
DC and kill those cells that are not fully mature. Through this process, NK cells 
contribute to maintain the reservoir of immunogenic DC by killing potentially tolerogenic 
DC thus optimizing effector anti-tumour responses (Moretta 2002; Moretta, Ferlazzo et 
al. 2006; Morandi, Mortara et al. 2012). 
The functionality of NK cells is fundamental for contrasting the growth and metastatic 
process of several types of cancers. For example, several reports have elucidated the role 
of NK cells in killing cancer cells in murine models of melanoma, colon cancer, lung 
cancer, and breast cancer (Azogui, Avril et al. 1991; Pham-Nguyen, Yang et al. 1999; 
Velthuis, Stitzinger et al. 2003; Carrega, Pezzino et al. 2009; Frings, Van Elssen et al. 
2011; Kim, Kim et al. 2011; Takeda, Nakayama et al. 2011; Vesely, Kershaw et al. 2011; 
Roberti, Mordoh et al. 2012; Srivastava, Sharma et al. 2012). There are several NK 
receptors, such as DNAM-1, CD155, CD16, CD69, NKp30, and NKp46, whose surface 
expression is fundamental for maintaining cancer immune surveillance (Clausen, 
Vergeiner et al. 2003; Garcia-Iglesias, Del Toro-Arreola et al. 2009; Lakshmikanth, 
Burke et al. 2009; Chan, Andrews et al. 2010; Levy, Roberti et al. 2011; Pfeiffer, Seitz et 
al. 2011; Gleason, Verneris et al. 2012; Park, Park et al. 2013). In this regard, some 
groups investigated the phenotypic profile and functions of intratumoural NK cells in 
primary human tumours of non-small cell lung carcinoma (NSCLC) by using the NK cell 
marker NKp46. The data showed that these intratumoural NK cells display a deeply 
altered phenotype that strongly contributed to the cancer progression in patients 
(Platonova, Cherfils-Vicini et al. 2011). These results strengthen the critical role of the 
cancer microenvironment and its composition, and identify NK cells as important 
predictive biomarkers of neoplastic disease progression. A recent study performed in a 
mouse tumour model elucidated the importance of NK cells in a vaccination strategy 
against lung cancer. A survivin-based vaccination, coupled to the use of novel form of the 
4-1BBL co-stimulatory molecule as an adjuvant has been effective in completely 
suppressing Lewis lung carcinoma (3LL)progression. The vaccine efficacy was correlated 
with potent killing responses of NK cells (Srivastava, Sharma et al. 2012). Another report 
highlighted the role of NK cells of lung tissue during the generation of lung metastases 
from melanoma, elucidating that IFN-γ production by these lung-resident NK cells 
markedly repressed the formation of metastases (Takeda, Nakayama et al. 2011). 
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Defects in NK cell number or in their phenotype are events that dictate the fate of 
neoplastic diseases other than lung carcinoma. Many investigations defined the key role 
of NK cell receptors in melanoma and several studies reported possible mechanisms by 
which melanoma cells escape killing activity of NK cells (Balsamo, Pietra et al. 2012; 
Pietra, Vitale et al. 2012; Wang, Cui et al. 2012). Nevertheless, strategies aimed at 
promoting and sustaining the melanoma-specific killing activity of NK cells are only at 
early stages or poorly effective. Recently it has been shown an active role of the 
chemotherapeutic drug dacarbazine, largely used for this type of neoplastic disease, in 
activating the expression of NK1G receptor on NK cell surface, thus restoring the killing 
activity of NK cells toward melanoma cells (Hervieu, Rebe et al. 2013). Similar 
encouraging approaches have been recently started for breast cancer by using the 
chemotherapeutic agent Cetuximab. This drug was shown to be effective in promoting 
NK cell killing activity in high relapse rate, triple negative breast cancer patients. Indeed, 
Cetuximab restored IL-2/IL-15-mediated NK cell killing activity, thus markedly 
improving the outcome of these patients (Roberti, Rocca et al. 2012). Taken together, 
these data strongly support a key role of NK cells in tumour progression. Indeed, when 
activated, NK cells fight malignant cells inside the microenvironment by direct killing as 
well as by contrasting the generation of metastatic foci. 
Myeloid Derived Suppressor Cells. 
Myeloid Derived Suppressor Cells (MDSCs) were originally identified in tumour-bearing 
mice as cells that co-express CD11b and Gr1, however their phenotype in cancer is rather 
different (Peranzoni, Zilio et al. 2010; Greten, Manns et al. 2011). Currently, two main 
MDSC subtypes have been reported, granulocytic and monocytic MDSC (G- and M-
MDSC) . The G-MDSC are defined by the phenotype CD11b+Gr-1hiLy-6G+Ly-
6CloCD49d−, whereas the M-MDSC are characterised by the phenotype CD11b+Gr-1hiLy-
6G−Ly-6ChiCD49d+ (Gabrilovich, Ostrand-Rosenberg et al. 2012).In humans the situation 
is even more complex, but M-MDSC are predominantly CD14+and G-MDSC are CD15+, 
both being CD33+HLA-DR− (Schmielau and Finn 2001; Zea, Rodriguez et al. 2005; 
Mirza, Fishman et al. 2006; Filipazzi, Valenti et al. 2007; Mandruzzato, Solito et al. 2009; 
Poschke, Mougiakakos et al. 2010; Gowda, Godder et al. 2011). In both mice and humans 
the G-MDSC represent the major subset of circulating and expanding MDSC 
(Gabrilovich, Ostrand-Rosenberg et al. 2012). Almost all patients and animal models with 
cancer displayed a higher amount of  G-MDSC compared with M-MDSC (approximately 
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75% vs. approximately 25%) (Schmielau and Finn 2001; Kusmartsev, Nefedova et al. 
2004; Youn, Nagaraj et al. 2008; Rodriguez, Ernstoff et al. 2009). Increased production of 
intra-tumoural granulocyte (G-CSF) or granulocyte–macrophage (GM-CSF) colony-
stimulating factors may account for the difference observed in G-MDSC and M-MDSC 
levels (Dolcetti, Peranzoni et al. 2010; Meyer, Sevko et al. 2011). Inappropriate levels of 
G-CSF have been reported for many different human tumours, including pancreatic, 
oesophageal, gastric and glioma (Gabitass, Annels et al. 2011; Raychaudhuri, Rayman et 
al. 2011). Waight et al. (Waight, Hu et al. 2011) identified tumour-derived G-CSF as a 
key driver of G-MDSC accumulation in mice. Despite this, the frequency of each MDSC 
subset seems to be influenced by the type of cancer patients with renal cancer have 
immunosuppressive PMN-MDSCs(Rodriguez, Ernstoff et al. 2009), while M-MDSCs 
circulate in the blood of patients with melanoma, multiple myeloma, prostate cancer, 
hepatocellular carcinoma, and head and neck cancer (Serafini, Meckel et al. 2006; 
Filipazzi, Valenti et al. 2007; Hoechst, Ormandy et al. 2008; Mandruzzato, Solito et al. 
2009; Vuk-Pavlovic, Bulur et al. 2010).  
Both M-MDSC and G-MDSC use antigen-specific and antigen non-specific mechanisms 
to regulate immune responses. Interestingly, G-MDSC and M-MDSC can inhibit T-
effector cells through different modes of action, although these mechanisms are not 
exclusively applied by one of the two subtypes (Gabrilovich and Nagaraj 2009; 
Gabrilovich, Ostrand-Rosenberg et al. 2012). Production of ROS is mainly used by G-
MDSC, whereas the generation of NO and secretion of ARG-1 has been predominantly 
established for M-MDSC (Movahedi, Guilliams et al. 2008; Youn, Nagaraj et al. 2008; 
Dolcetti, Peranzoni et al. 2010). Production of ROS by MDSC is mediated through the 
increased activity of NADPH oxidase (NOX) 2; and the up-regulation of ROS by Gr-
1+CD11b+MDSC isolated from seven different tumour models and by 
CD11b+CD14−CD33+MDSC in patients with head and neck cancer has been already 
identified. These MDSC showed significantly higher expression of the NOX2 subunits 
p47phox and gp91phox compared with immature myeloid cells from tumour-free mice 
(Corzo, Cotter et al. 2009).In the absence of NOX2 activity, MDSC lost the ability to 
control T-cell hyporesponsiveness and differentiated into mature DC. Indeed, MDSC 
from gp91−/−mice are not able to induce T-cell tolerance, confirming the role of ROS in 
T-cell suppression (Nagaraj, Gupta et al. 2007). In addition the cooperative activity of 
ROS with NO forms peroxynitrite (Kusmartsev, Nefedova et al. 2004; Gabrilovich and 
Nagaraj 2009; Gabrilovich, Ostrand-Rosenberg et al. 2012) that leads to the nitration of 
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tyrosines in the T-cell receptor (TCR)–CD8 complex. This reaction might affect the 
conformational flexibility of TCR-CD8 and its interaction with peptide-loaded MHCI, 
rendering the CD8+T cells (cytotoxic T lymphocytes; CTL) unresponsive to antigen-
specific stimulation (Nagaraj, Gupta et al. 2007). Indeed, nitration inhibits the binding of 
processed peptides to tumour cell-associated MHC, and as a result, tumour cells become 
resistant to antigen-specific TIL (Lu, Ramakrishnan et al. 2011). Furthermore, 
peroxynitrite leads to the nitration of CCL2 chemokines thereby inhibiting TIL trafficking 
into the tumour, resulting in trapping of antigen-specific CTL in the tumour-surrounding 
stroma (Molon, Ugel et al. 2011).Another mechanism by which MDSC can interfere with 
T-cell trafficking is the expression of the disintegrin and metalloproteinase domain 
(ADAM) 17, which decreases CD62 ligand expression and renders T cells immobile 
(Gabrilovich, Ostrand-Rosenberg et al. 2012). 
The suppressive activity of ARG-1 is based on its fundamental role in the hepatic urea 
cycle, metabolizingl-arginine tol-ornithine. Expression of ARG-1 has been reported to 
down-regulate TCR cell surface expression by decreasing CD3 ζ-chain 
biosynthesis(Rodriguez, Zea et al. 2002). This induces an arrest of T cells in the G0–G1 
phase of the cell cycle, associated with a deficiency of protein kinase complexes that are 
important for G1 phase progression(Rodriguez, Ernstoff et al. 2009).In vivo, the depletion 
of CD14−CD15+G-MDSC re-established CD3ζ-chain biosynthesis and T-cell growth; 
further emphasizing the detrimental role that these MDSC play in cancer (Zea, Rodriguez 
et al. 2005). Cancer-expanded MDSC can also induce anergy in NK cells through 
membrane bound TGF-β, signal transducer and activator of transcription 5 (STAT5) 
activity, ARG-1 or via the NKp30 receptor (Liu, Yu et al. 2007; Hoechst, Voigtlaender et 
al. 2009; Oberlies, Watzl et al. 2009; Alizadeh, Zhang et al. 2010). The MDSC can 
suppress NK cell cytotoxicity by inhibiting NKG2D and interferon-γ (IFN-γ) production 
in models of glioma (Alizadeh, Zhang et al. 2010). 
Another type of immunosuppression modulated by MDSC is the activation and expansion 
of TREG cells. Mouse studies in vivo suggested that MDSC support the de novo 
development of TREG cells through TGF-β-dependent(Huang, Pan et al. 2006; Yang, Cai 
et al. 2006)and -independent pathways (Serafini, Mgebroff et al. 2008). Yang et al. 
reported that suppression of Gr-1+CD11b+MDSC isolated from ovarian-carcinoma-
bearing mice was dependent on the presence of CD80 on the MDSC and involved 
CD4+CD25+TREG cells and CD152, suggesting a relationship between MDSC and TREG 
cells (Yang, Cai et al. 2006). In a mouse colon carcinoma model, IFN-γ activated Gr-
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1+CD115+M-MDSC were shown to up-regulate MHCII and produce IL-10 and TGF-β to 
mediate the development of tumour-induced CD4+CD25+TREG cells. The production of 
NO by Gr-1+ (Poschke, Mao et al. 2012)dispensable for TREG-cell induction (Huang, Pan 
et al. 2006). These data exemplify the relationship between MDSC and TREG cells.  
Finally MDSCs have been demonstrated to exert their immunosuppressive functions 
trough DCs impairment. In many cancer patients the numbers of mature DC are reduced 
and DC function is deficient. Although multiple factors are likely to contribute to DC 
dysfunction, evidence is accumulating that MDSC–DC cross-talk may at least be partially 
responsible. In vitro studies in which mouse MDSC were differentiated from ckit+ bone 
marrow progenitor cells in the presence of IL-4, GM-CSF, and PGE2demonstrated that 
the numbers of mature DC decreased proportionately to the increasing numbers of MDSC 
(Sinha, Clements et al. 2007). The differentiation of murine DC was similarly reduced 
when mixtures of murine myeloid cells were treated with LPS and IFNγ (Greifenberg, 
Ribechini et al. 2009). IL-10 produced by hepatocellular carcinoma-induced MDSC has 
also been shown to decrease DC production of IL-12 (Hu, Gan et al. 2011). Since MDSC 
and DC share a common progenitor cell, the reduction in mature DC observed in cancer 
patients may be due to the skewing of the common MDSC/DC progenitor towards the 
preferential differentiation of MDSC at the expense of DC. 
Recent in vitro studies assessing the effects of MDSC obtained from cancer patients on 
DC differentiation further support a role for MDSC–DC cross-talk. Studies with MDSC 
from melanoma patients demonstrated that MDSC impaired DC maturation by reducing 
antigen uptake, preventing migration of immature and mature DC, blocking the ability of 
DC to induce IFNγ-producing T cells, and altering DC cytokine production towards an 
anti-inflammatory phenotype (Poschke, Mao et al. 2012). DC production of the pro-
inflammatory cytokine IL-23 and its downstream induction of Th17 cells may contribute 
to the effects of MDSC on DC. Further studies are needed to clarify the role of MDSC in 
regulating DC function, and the complexity of the tumour microenvironment with respect 
to the milieu of cytokines and chemokines is likely to make this task difficult. 
Collectively, the data show that MDSC can employ a diverse set of distinct mechanisms 
to affect tumour cells, endothelial cells and immune cells to create a local environment 
that sustains tumour growth and survival while suppressing anti-tumour immune 
responses. 
There are many evidences that the immunosuppressive role of MDSC is dependent on 
STAT transcription factors. By using STAT6−/−mice models transplanted with 4T1 cancer 
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cells (Sinha, Clements et al. 2005)it has been shown that MDSC render 4T1 mammary 
tumours poorly immunogenic by suppressing the activation of CD4+and CD8+T cells. The 
involvement of STAT signalling in the immunosuppressive activity of MDSC in cancer 
has been further highlighted in studies on human head and neck squamous cell carcinoma 
and breast cancer, suggesting a pivotal role of STAT3 and STAT1 pathways, 
respectively, for MDSC suppressive activity within cancer microenvironment (Hix, 
Karavitis et al. 2013; Vasquez-Dunddel, Pan et al. 2013).  
1.4 Role in cancer progression 
Immune cell infiltration within a solid tumour is a naturally occurring event, when cells 
belonging to immune system enter within the tumour microenvironment by means of 
tumour-forming blood vessels and/or extravasation. This event can sometimes lead to 
blocking of cancer progression and thus limit or even prevent the generation of metastasis 
(Vesely, Kershaw et al. 2011).  
Multiple lineages of immune cells are involved in antitumour responses. It has long been 
established that NK cells are able to kill tumour cells in various cancer models (Pross and 
Lotzova 1993; Stojanovic and Cerwenka 2011). Similarly, cytotoxic T lymphocytes can 
detect “abnormal” tumour antigens expressed on carcinoma cells and target those cells for 
destruction (Weigelin, Krause et al. 2011). Antigen-presenting cells, and dendritic cells in 
particular, process and present tumour derived antigens in the context of MHC class I 
molecules to activate CD8+ T cells via a mechanism known as cross presentation 
(Flinsenberg, Compeer et al. 2011). Apart from direct killing of carcinoma cells, the 
activated CD8+ T cells may also inhibit angiogenesis by secreting IFN-γ (Qin, 
Schwartzkopff et al. 2003). B cell activation and differentiation into antibody-producing 
plasma cells as well as T- and B cell memory are each important components of long 




In general, all these events occur when tumour progression is at early stages as a result of 
host immune surveillance. At this point, if the organism is able to generate a prompt 
tumour-specific immune response, cancer progression is contrasted by immune forces and 
sometimes inhibited. In many cases, unfortunately, the host is unable to generate an 
effector immune response toward the tumour, due to its ability to activate 
immunosuppressive mechanisms that circumvent or dampen immunity, thus resulting in 
to tumour escape from host immune surveillance. In this scenario, the balance of immune 
populations endowed with effector vs. suppressive activities at the tumour site, is a 
critical parameter predicting cancer progression (Schiavoni, Gabriele et al. 2013) (Figure 
2 
Figure 2: Multiple roles of the immune microenvironment during tumour 
development(Chew, Toh et al. 2012).  
The immune system initially eliminates tumour cells via cytotoxic T cell and NK cell killing mechanisms 
(immune surveillance). This is obtained with the help of antigen-presenting cells (APC) such as the 
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dendritic cells, antibodies expressed by B cells, and inflammatory cytokines including IFN-γ and IL-2 
which activate the local immune response. However, with the progressive accumulation of tumour cell 
mutations and modifications to the microenvironment, the tumour cells can eventually “escape” from 
immunesurveillance. Multiple lineages of immune cells including myeloid-derived suppressor cells 
(MDSC), tumour-associated macrophages (TAM), and regulatory T cells (TREG), as well as various immune 
mediators such as TNF-α, IL-6, CXCL-1, CXCL-5, VEGF, and MMP, are responsible for modelling a 
favourable microenvironment for tumour growth. Recent findings also show that the immune response 
continues to play an important role in established tumours via mechanisms that involve cytotoxic T cells 
and NK cells, as well as IFN-γ, CCL5, CXCL10, and toll-like receptors. 
Initial Elimination/Equilibrium Phase of immune response 
The period during which tumour cells are constantly being killed and controlled by the 
The “Escape” Phase 
 and progression are influenced by modifications to tumour 
immune system is referred to as the “equilibrium phase.” The tumour can stay dormant 
for long periods of time until the microenvironment becomes permissive for growth 
(Almog 2010). This tumour dormancy is effectively explained in a spontaneous 
melanoma mouse model wherein tumour cells disseminate early but remain dormant at 
remote metastatic sites (Eyles, Puaux et al. 2010). Dormancy is partly controlled by 
cytotoxic CD8+ T cells, since depletion of CD8+ T cells results in faster outgrowth of 
visceral metastases (Eyles, Puaux et al. 2010). However, the continuous control of tumour 
cells exerts a selective pressure which eventually favours the more aggressive tumour 
cells. For example, these tumour cell variants may mutate surface antigens in order to 
become less immunogenic via a process termed “immunoediting.” The equilibrium phase 
will thus eventually reach a state of exhaustion when the more aggressive and less 
immunogenic tumour cells are able to “escape” immune surveillance (Chew, Toh et al. 
2012). 
Tumour development
parenchymal cells or their microenvironment. One important mechanism of escape from 
immune surveillance is the selection of poorly immunogenic tumour cells (Browning and 
Bodmer 1992). Alternatively, modification of the microenvironment may also result in 
the acquisition of a “pro-cancer” profile that encourages tumour outgrowth. These pro-
cancer modifications include the expression of anti-apoptotic molecules which prevent 
tumour cell death (Reed 1999); growth factors which stimulate tumour growth (Zhang, 
Nie et al. 2010), and immunosuppressive mediators such as VEGF, transforming growth 
factor-β (TGF-β), interleukin (IL)-10, indoleamine 2,3-dioxygenase (IDO), and 
programmed cell death-ligand 1 (PD-L1) which suppress antitumour immunity (Ben-
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Baruch 2006; Gajewski, Meng et al. 2006). TLR pathways such as TLR4 activation on 
tumour cells have also been shown to directly stimulate tumour growth (Huang, Zhao et 
al. 2005). Furthermore, as a result of imbalances between pro- and antiangiogenic factors, 
the microvasculature formed within the tumour microenvironment is often leaky and 
dysfunctional (Goel, Duda et al. 2011), thus limiting T-cell infiltration and drug diffusion 
into the tumour. The tumour microenvironment is further shaped by resident leukocytes 
and the ongoing recruitment of different immune cell subsets. For example, the 
recruitment of TREG and MDSC contributes to immunosuppression within the tumour 
microenvironment (Zou 2006; Ostrand-Rosenberg and Sinha 2009). MDSC for instance 
act on multiple levels to inhibit naïve T-cell proliferation and differentiation, to block T-
effector cell functions, and to induce TREG via the expression of IL-10 and TGF-β 
(Ostrand-Rosenberg and Sinha 2009). TAM (with a unique M2-like phenotype) have 
similarly been shown to correlate with poor prognosis in various cancers due to their 
immunosuppressive and angiogenic or lymphangiogenic properties (Mantovani, Schioppa 
et al. 2006). The contribution of other leukocyte subsets to shaping the tumour 
microenvironment is less clear. For istance, while the role for Th17 cells in cancer is 
rather controversial (Middleton, Annels et al. 2012), investigators have reported that these 
cells are associated with a poor prognosis in colorectal cancer (Tosolini, Kirilovsky et al. 
2011). Previous reports have even implicated B cells in enhanced tumour metastasis 
(Staquicini, Tandle et al. 2008; Olkhanud, Damdinsuren et al. 2011). On the other hand, 
the tumour microenvironment has been reported to prevent DC maturation hence making 
them incapable of functioning as effective APC to trigger antitumour immunity (Yang 
and Carbone 2004). Inflammation has been implicated in the development of cancers 
since the seminal observation made by Virchow in 1863 (Balkwill and Mantovani 2001; 
Aggarwal, Shishodia et al. 2006) that chronic inflammation creates a microenvironment 
conducive to tumourigenesis. The inflammation associated with chronic infections such 
as Helicobacter pylori or hepatitis B virus promotes the respective development of gastric 
and liver cancers (Chemin and Zoulim 2009; Hatakeyama 2009). Chronic inflammation 
associated mechanisms of tumourigenesis include cellular transformation, proliferation, 
invasion, angiogenesis, chemoresistance, metastasis, and inhibition of apoptosis 
(Aggarwal, Shishodia et al. 2006; Mantovani 2010). Proinflammatory cytokines such as 
IL-6, IL-1α, and IL-8, as well as various chemokines, are known to favour tumour growth 
and progression (Balkwill and Mantovani 2001; Aggarwal, Shishodia et al. 2006). The 




aspects of tumourigenesis including cellular transformation, proliferation, invasion, and 
metastasis (Aggarwal, Shishodia et al. 2006). The role of IL-6 and STAT-3 as anti-
apoptotic factors in various cancers is also well recognized (Hodge, Hurt et al. 2005). 
Chemokines such as CXCL1 and CXCL8 are able to enhance tumour cell proliferation 
(Payne and Cornelius 2002); CXCL5 and CXCL12 attract neutrophils and MDSC (Yang, 
Huang et al. 2008), while CXCL12 promotes the migration of tumour cells that express 
the cognate receptor CXCR4 (Balkwill 2004). Many of these immunological mediators 
are regulated by transcription factor NF-κB, which is constitutively active in many 
cancers and is inducible by various carcinogens including viruses (Aggarwal, Shishodia et 
al. 2006; Ben-Neriah and Karin 2011). 
Tumour metastasis is the primary cause of cancer-related death (Jemal, Siegel et al. 
Established Tumours 
he immune system fails to control tumour formation, the immune 
2008). Epithelial-to-mesenchymal transition (EMT) of cancer cells is associated with 
enhanced cell migration, local invasion and distant metastasis, and expression of EMT 
markers correlates with poor prognosis (Micalizzi and Ford 2009). EMT is a common 
process in early embryogenesis and carcinoma progression (Thiery, Acloque et al. 2009). 
During EMT, the carcinoma cells undergo morphological changes that confer enhanced 
motility and reduced intercellular adhesion which enable local invasion and distant 
metastasis (Savagner 2010). A recent study in a spontaneous melanoma model showed 
that tumour recruitment of MDSC promotes EMT (Toh, Wang et al. 2011). In particular, 
it has been found that granulocytic (G)-MDSC induce EMT in vitro and in vivo via 
multiple pathways involving TGF-β1, epidermal growth factor (EGF), and hepatocyte 
growth factor (HGF) (Toh, Wang et al. 2011). Other immune cells such as activated CD8+ 
T cells (Santisteban, Reiman et al. 2009) and macrophages (Bonde, Tischler et al. 2012) 
have also been shown to stimulate EMT in tumour-bearing mice. Together, these data 
emphasize the intimate relationship between host immune responses and the 
microenvironment in modelling tumour development and progression. 
At the same time as t
response within the microenvironment of established tumours remains an important factor 
in determining the outcome of cancer. Regression of established liver tumours by 
induction of CD8+ T-cell responses with peptide-based immunotherapy was reported in 
several mouse models (Qian, Li et al. 2001; Belnoue, Guettier et al. 2004). Recent 
genomics studies in various human tumours including breast cancer have identified 
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immunological parameters as important determinants of disease outcome (Chew, Tow et 
al. 2010; Hsu, Kim et al. 2010; Suzuki, Kachala et al. 2011). Several studies have 
underlined the importance of the tumour microenvironment on the clinical evolution of 
Hepatocellular Carcinoma (HCC) (Xu, Shen et al. 2008; Chew, Tow et al. 2010). Chew et 
al. discovered an intriguing association between the expression of intratumoural pro-
inflammatory genes and patient survival (Chew, Tow et al. 2010; Chew, Chen et al. 
2012). In 172 HCC patients, they demonstrated that a 14-gene immunological signature is 
predictive of patient survival, especially at the early stages of the disease (Chew, Chen et 
al. 2012). These 14 immune genes encode chemokines CXCL10, CCL5, and CCL2; 
cytokines IFNG, TNF, and IL6; pattern recognition receptors TLR3 and TLR4; T cell 
markers CD8A and TBX21, and NK cell marker NCR3. Of importance, in this study 
IFN-γ and TLR3 ligand-induced intra-tumour chemokine expression was shown to 
promote infiltration by cytotoxic T cells and NK cells to enhance tumour cell apoptosis 
and reduce their proliferation (Chew, Chen et al. 2012). The immune microenvironment 
of noncancerous hepatic tissues has also been shown to impact on the development of 
venous metastases in HCC patients (Budhu, Forgues et al. 2006). A pro-inflammatory 
phenotype combined with tumour infiltration by cytotoxic lymphocytes is associated with 
a better prognosis in various cancers (Pages, Galon et al. 2010; Chew, Chen et al. 2012). 
Tumour infiltration by T cells has now been linked with favourable prognosis in 
colorectal cancer (Galon, Costes et al. 2006), melanoma (Clemente, Mihm et al. 1996), 
breast cancer (Menegaz, Michelin et al. 2008), ovarian cancer (Zhang, Conejo-Garcia et 
al. 2003), and lung cancer (Dieu-Nosjean, Antoine et al. 2008). Recent studies in liver 
and breast cancers have identified an important correlation between the densities and 
distribution of T and B cells with a favourable prognosis (Martinet, Garrido et al. 2011; 
Schneider, Teufel et al. 2012). Chew et al. revealed that in HCC there is a correlation 
between patient survival and the intratumour densities of T cells and NK cells. It is 
important to consider hat tumour infiltration by cytotoxic lymphocytes is often 
orchestrated by chemokines expressed within the tumour microenvironment. In HCC, it 
has been demonstrated that stimulation with cytokines in conjunction with TLR activation 
can promote inflammation and chemokine production in tumours (Chew, Chen et al. 
2012). Chemokine mediated tumour infiltration by cytotoxic lymphocytes has also been 
demonstrated by several investigators (Hirano, Iwashita et al. 2007; Harlin, Meng et al. 
2009). In a cutaneous melanoma model, it has been further shown that chemotherapy 




tumour control (Hong, Puaux et al. 2011). In contrast, several studies have evidenced the 
key role played by chemokines during metastasis, particularly among tumour cells that 
express chemokines receptors CXCR3 and CXCR4 (Koizumi, Hojo et al. 2007; Fulton 
2009). The role of the proinflammatory microenvironment in tumour control therefore 
appears to be context dependent and will require further detailed investigation. 
1.5 Melanoma microenvironment 
Malign id progression, metastasis to distant organs, ant melanoma is characterised by a rap
and resistance to chemo- and radiotherapy. The definition of the immunogenic capacities 
of melanoma cells should allow a successful application of different immunotherapeutic 
strategies of this type of cancer. However, the overall results of immunotherapeutic 
clinical studies are not satisfactory. These paradoxical observations are supposed to be 
due to the profound immunosuppression mediated by different mechanisms dealing with 
alterations in tumour and surrounding stroma cells. This complex immunosuppressive 
network is supposed to be stimulated by chronic inflammatory conditions developing in 
the tumour microenvironment (Figure3) (Umansky and Sevko 2012). Indeed, chronic 
inflammation has been demonstrated to correlate with the tumour onset and progression 
(Grivennikov, Greten et al. 2010; Mantovani 2010). 
Figure 3: Melanoma microenvironment (Umansky and Sevko 2012) 
st cells that include various Soluble mediators of chronic inflammation secreted by the melanoma and ho
cytokines (like IL-1β, IL-6, IFN-γ, TNF-α etc.), chemokines (such as CCL2, CCL3, CXCL8 etc.), and 
growth factors (e.g., TGF- _, VEGF GM-CSF etc.) can induce the migration in tumour lesions and 
activation of many immunosuppressive leucocytes such as myeloid-derived suppressor cells (MDSC), 
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regulatory T cells (TREG), M2 polarized macrophages (TAM), regulatory dendritic cells (regDC), and Th2 
lymphocytes. Activated MDSC, producing high amounts of nitric oxide (NO) and reactive oxygen species 
(ROS) as well as expressing elevated levels of arginase (ARG)-1 considerably contribute to the inhibition 
of antitumour responses mediated by effector CD4 (Th1) and CD8T cells by inducing a down-regulation of 
the TCRζ-chain, an arginine deprivation, and apoptosis. 
The role of chronic inflammation in melanoma development 
red to be strongly related to Chronic infection and inflammation have long been conside
cancer progression; however, only during the last decade this complex association has 
commenced to be deciphered (Tan and Coussens 2007; Mantovani 2010; Rook and 
Dalgleish 2011). Although human malignant skin melanoma is not generally associated 
with apparent inflammation, recent publications have highlighted the critical importance 
of a chronic inflammatory microenvironment, especially the role of particular cytokines 
and chemokines, for melanoma initiation and progression (Navarini-Meury and Conrad 
2009). For istance, it has been observed that patients with advanced metastatic melanoma 
display a Th2 pattern of immune homeostasis (mirroring a state of chronic inflammation) 
as reflected by the accumulation of the cytokines IL-4, IL-5, IL-10 and IL-13 as well as 
the chemokines CCL5 (RANTES), CCL11 (Eotaxin) and CXCL10 (IP-10) in patients’ 
plasma (Nevala, Vachon et al. 2009). In contrast, healthy donors or patients with 
completely resected melanoma were characterised by Th1 biased immune homeostasis. 
The reprogramming of immunity towards the dominance of Th2 cytokines could be 
mediated by tumour-derived VEGF leading to tumour progression and metastasis 
(Nevala, Vachon et al. 2009). Moreover, such Th2 bias has been also observed in patients 
with renal cell carcinoma (Tatsumi, Kierstead et al. 2002):of interest, both these 
malignancies were characterised by increased levels of VEGF production 
(Mahabeleshwar and Byzova 2007; Milella and Felici 2011). Melanoma cells have been 
demonstrated to produce a variety of chemokines including CCL2, CCL5, CXCL1, 
CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8, and CXCL10 (Richmond, Yang et 
al. 2009). Although at the beginning chemokines were described just with respect to the 
leucocyte migration, it became soon quite clear that chemokines are produced by different 
cell types. Chemokines released by melanoma cells have been found to induce tumour 
growth, angiogenesis, metastasis and alterations in cellular components of the tumour 
microenvironment (Murakami, Cardones et al. 2004; Navarini-Meury and Conrad 2009; 
Talmadge 2011). Furthermore, melanoma cells were able to influence fibroblasts and 
macrophages in the tumour stroma to produce a number of chemokines such as CCL2, 
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CXCL8 and CXCL12 as well as growth factors like VEGF, TGF-β or tumour necrosis 
factor (TNF)-α and cytokines (IL-1, IL-6 or IL-8). On the other hand, stromal cells can 
further stimulate the chemokine production by tumour cells creating thereby an autocrine 
and paracrine loop of the tumour growth stimulation (Labrousse, Ntayi et al. 2004; 
Raman, Baugher et al. 2007; Somasundaram and Herlyn 2009). Of importance, 
chemokine expression was found to be steadily enhanced during melanoma progression 
by the activation of the NF-kB family of transcription factors, whereas blocking NF-kB 
signalling might strongly reduce the  chemokine concentration and suppress melanoma 
progression in different mouse models (Richmond, Yang et al. 2009; Yang, Splittgerber 
et al. 2010). Moreover, the discovery of other transcription factors such as activator 
protein 1(AP-1)and STAT3 that together with the NF-kB can induce the production of 
chemokines and other proinflammatory mediators like TNF-α, IL-1, IL-6, IL-8, 
cyclooxygenase-2 (COX-2), matrix metalloproteases, VEGF have provided the molecular 
basis for the link between chronic inflammation and cancer. This cross-talk is indicated 
by (i) the induction of tumour development under chronic inflammatory conditions and 
(ii) the formation of chronic inflammatory microenvironment in tumour lesions, which 
strongly stimulates tumour growth and metastasis (Baniyash 2006; Grivennikov, Greten 
et al. 2010; Mantovani 2010; Allavena, Germano et al. 2011; Ben-Neriah and Karin 2011; 
Rook and Dalgleish 2011). Moreover, recent publications indicated that several 
oncogenes are able to promote uncontrolled cell proliferation and stimulate their 
resistance to apoptosis as well as to activate a cascade of proinflammatory molecules. In 
particular, components of the RAS-RAF signalling pathway have been demonstrated to 
trigger NF-kB activation and the following enhanced production of proinflammatory 
cytokines and chemokines (Sparmann and Bar-Sagi 2004; Sumimoto, Imabayashi et al. 
2006; Haluska, Pemberton et al. 2007). This can results into a never ending chronic 
inflammatory process as reflected by the constant release of cytokines, chemokines and 
growth factors, by the recruitment and activation of myeloid immunosuppressive cells 
like MDSCs and TAMs as well as by the stimulation of pathways promoting melanoma 
growth and metastasis (Baniyash 2006; Sawanobori, Ueha et al. 2008; Sica, Larghi et al. 
2008; Allavena, Germano et al. 2011). 
MDSC in the inflammatory melanoma microenvironment 
The number and activity of Gr1+CD11b+ MDSCs in melanoma lesions (skin tumours and 
lymph node metastases) as well as in the spleen and bone marrow it has been already 
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investigated (Meyer, Sevko et al. 2011). A remarkable accumulation of MDSCs among 
tumour infiltrating leucocytes has been demonstrated and significantly correlate with the 
increasing weight of these primary tumours. Furthermore, quickly growing tumours 
showed elevated MDSC frequencies within infiltrating leucocytes. Significantly high 
percentages of MDSCs were detected also in metastatic lymph nodes as well as in the 
spleen and bone marrow of melanoma-bearing mice in the ret transgenic spontaneous 
model(Meyer, Sevko et al. 2011). Similar observations on MDSCs recruitment have been 
also demonstrated in different mouse models of tumour transplantation and in cancer 
patients (Filipazzi, Valenti et al. 2007; Gabrilovich and Nagaraj 2009; Ostrand-Rosenberg 
2010; Peranzoni, Zilio et al. 2010; Poschke, Mougiakakos et al. 2010). These data 
indicate that an observed enhanced production of numerous inflammatory mediators 
during melanoma progression in ret transgenic mice and in other systems may attract 
MDSCs into tumour lesions. Furthermore, MDSC accumulation in the site of chronic 
inflammation has been previously described in a mouse chronic inflammatory model 
(Baniyash 2006). One of the important consequences of the increased MDSC proportion 
in tumour-bearing hosts might be diminished numbers of mature myeloid cells like DCs 
(Gabrilovich and Nagaraj 2009; Ostrand-Rosenberg 2010). Indeed, it has recently 
observed a significant reduction in numbers of mature DCs in melanoma lesions and 
lymphoid organs from ret transgenic mice (Zhao, Falk et al. 2009). Enriched in the 
tumour microenvironment MDSCs are able to display a high level of activation reflected 
by intensive NO production, and ARG-1 expression associated with their strong capacity 
to suppress T cell activities in vitro assays (Rodriguez and Ochoa 2006; Serafini, Borrello 
et al. 2006; Gabrilovich and Nagaraj 2009; Ostrand-Rosenberg and Sinha 2009; Meyer, 
Sevko et al. 2011). One of the most important mechanisms of MDSC-mediated blocking 
of T-cell functions is associated with a remarkable decrease in the expression of T-cell 
receptor  ζ-chain (Rodriguez, Zea et al. 2002; Ezernitchi, Vaknin et al. 2006), which plays 
a critical role in coupling the TCR-mediated antigen recognition to diverse signal 
transduction pathways (Baniyash 2004). In ret melanoma model, a profound down-
regulation of TCR  ζ-chain expression has been detected in T lymphocytes infiltrating 
primary and metastatic lesions as well as in cells localised in lymphoid organs (Meyer, 
Sevko et al. 2011). Moreover, a decrease of  ζ-chain levels has been reported not only in 
T cells from patients with different tumour types (Nakagomi, Petersson et al. 1993; 
Whiteside 2004), but also in mice with chronic inflammation (Baniyash 2004; Ezernitchi, 
Vaknin et al. 2006), suggesting again an amazing resemblance of both pathological 
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processes. Furthermore, a direct MDSC inhibitory effect on TCR ζ-chain expression has 
been documented in vitro co-culture of MDSCs isolated from tumour-bearing mice or 
animals under chronic inflammatory conditions with normal T lymphocytes (Baniyash 
2004; Ezernitchi, Vaknin et al. 2006; Meyer, Sevko et al. 2011).. Taken together, all 
above mentioned findings suggest a strong linkage among developing tumours, chronic 
inflammation, and immunosuppression. 
1.6 Cancer therapy strategies targeting the tumour and the suppressive 
microenvironment 
Given the complex roles of the immunological microenvironment in tumourimmunity 
(Figure 1), developing methods for targeting the relevant effector molecules or pathways 
for cancer treatment remains challenging. Indeed, the limited success of cancer 
immunotherapy to date can primarily be attributed to three main factors: (1) poor host 
responses towards tumour antigens, (2) low infiltration of effector cells into solid 
tumours, and (3) the intrinsically immunosuppressive tumour microenvironment. 
Reversing the immune responses from tumour protection towards tumour rejection seems 
to be the key for effective cancer immunotherapy (Mantovani, Romero et al. 2008; 
Quezada, Peggs et al. 2011; Gajewski 2012). Manipulation of the tumour 
microenvironment will therefore be an important consideration for achieving optimal 
antitumour responses with future treatments.  
Several cases of spontaneous regression associated with specific antitumour immune 
responses have been reported in various cancers (Bodey 2002; Saleh, Renno et al. 2005; 
Kalialis, Drzewiecki et al. 2009). Efforts to activate local adaptive immune responses in 
tumours have obtained some success, and cell-based therapies such as adoptive T-cell 
transfer have shown convincing signs of efficacy in treating metastatic melanoma patients 
(Rosenberg and Dudley 2009). DC-based vaccines represents a new and promising 
immunotherapeutic approach, explored in pre-clinical and clinical studies, for treatment 
of advanced cancer as well as for prevention of cancer (Perrotta, Falcone et al. 2004; 
Perrotta, Bizzozero et al. 2007; Palucka and Banchereau 2013).Recent developments in 
cancer immunotherapies have now also begun to explore the use of NK cells (Lee and 
Gasser 2010; Gillgrass and Ashkar 2011). Cancer vaccines aim to induce immune 
responses against tumour-associated antigens and several such vaccines are currently 
under development to treat various cancers (Schreiber, Raez et al. 2010; Slingluff 2011). 
However, the low immunogenicity of most tumour antigens represents a major difficulty 
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in developing potent cancer vaccines. Intensive research will be needed to improve the 
specificity and effectiveness of these type of therapy. Furthermore, the 
immunosuppressive tumour microenvironment limits the effectiveness of the antitumour 
immune responses induced by these cancer vaccines (Slingluff 2011). Therefore, 
manipulation of the tumour microenvironment either by enhancing the antitumour activity 
or blocking the immunosuppressive pathways is among the strategies pursued to obtain a 
more effective tumour therapy. Alternatively, vaccines that aim to control the chronic 
inflammation may serve as effective tumour preventing measures (Carcinoma 2010; Kane 
2010). One such example is the vaccination against hepatitis B which has successfully 
diminished the incidence of liver cancer in Taiwan since being introduced in 1984 (Chang 
2011). Vaccines against oncogenic human papilloma viruses (HPV) achieved similar 
success in preventing cervical cancer (Roden, Monie et al. 2006; Albers, Sinikovic et al. 
2009). 
Other cancer immunotherapies included the administration of immunostimulatory 
cytokines such as IL-2 and IFN-α (Antony and Dudek 2010; Moschella, Proietti et al. 
2010), as well as antibodies against tumour antigens (Grillo-Lopez, White et al. 2000; 
Hortobagyi 2005; de Cerio, Zabalegui et al. 2007), as adjuvants in combination with 
chemotherapy or cancer vaccines. The use of toll like receptor (TLR) ligands can trigger 
effective innate immune responses within tumours (Garland 2003; Meyer and Stockfleth 
2008; Adams 2009). For instance, some success has been achieved with the application of 
TLR7 agonists in the treatment of skin carcinoma (Garland 2003; Urosevic and Dummer 
2004). As intra-tumour expression of chemokines correlates with increased lymphocyte 
infiltration, transfection of chemokine cDNAs in murine tumour cells has shown 
promising tumour rejection in preclinical models (Braun, Chen et al. 2000). These recent 
advances in immunotherapy confirm that boosting the activity of tumour-infiltrating 
lymphocytes, which are reported to be exhausted in many cancers (Baitsch, Baumgaertner 
et al. 2011; Klebanoff, Acquavella et al. 2011), will be the key to the development of the 
most effective treatments. Such strategies may include the blockade of 
immunosuppressive pathways including PD/PDL (Hirano, Kaneko et al. 2005; Dotti 
2009), CTLA-4 (Lipson and Drake 2011; Prieto, Yang et al. 2012) and Cox 2 (Dempke, 
Rie et al. 2001; DeLong, Tanaka et al. 2003), TREG depletion prior to vaccination 
(Dannull, Su et al. 2005; Morse, Hobeika et al. 2008), or activation of the TLR pathway 
(Adams 2009; Woller, Knocke et al. 2011). For example, Ipilimumab, an antibody 
generated against CTLA-4, key negative regulator of T cell responses, has been recently 
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approved by the Food and Drug Administration (FDA) for the treatment of metastatic 
melanoma (Lipson and Drake 2011; Prieto, Yang et al. 2012). These interventions 
enhance the effectiveness of therapies by pushing the immunological balance towards 
antitumour responses within the microenvironment of cancers (Mantovani, Romero et al. 
2008; Zitvogel, Apetoh et al. 2008; Gajewski 2012). Some cancer drugs that were initially 
developed to induce carcinoma cell death were later found to act on the tumour 
microenvironment. One such example is Imatinibmesylate (Gleevec), a tyrosine kinase 
inhibitor which was developed to inhibit tyrosine kinase BCR-ABL in chronic myeloid 
leukemia (CML). Gleevec has been recently approved for the treatment of gastrointestinal 
stromal tumours (GIST) which exhibit a c-kit tyrosine kinase mutation. However, it has 
been shown later that clinical responses to Imatinib correlated with the inhibition of 
immunosuppressive enzyme Indoleamine 2,3 dioxygenase (IDO) and hence enhanced 
levels of T cell activation (Balachandran, Cavnar et al. 2011). Of interest, the class of 
small molecules that inhibit mTOR has recently been shown to exert antitumour activity 
by stimulating homeostatic proliferation of memory CD8+ T cells (Li, Rao et al. 2011). In 
addition, cytotoxic or genotoxic agents which induce cellular stress or DNA damage 
could release danger signals that are sensed by TLRs and activate innate immune 
responses (Gasser and Raulet 2006). Chemotherapeutic drugs have also been found to 
activate the immune system despite the prevailing view that these agents induce 
immunosuppressive effects. For example, low doses of cyclophosphamide inhibit TREG, 
and gemcitabine or 5-fluorouracil eliminate MDSC (Zitvogel, Kepp et al. 2011). 
Cyclophosphamide, paclitaxel, doxorubicin, and vinblastine given at regular intervals 
normalize the tumour-associated vasculature, thereby facilitating the delivery of drugs 
and recruitment of T lymphocytes (Bocci, Nicolaou et al. 2002). Gemcitabine can activate 
both the adaptive and humoral immunity to elicit meaningful antitumour responses in 
animal models (Lake and Robinson 2005). In melanoma patients responding to 
dacarbazine, we also found that chemotherapy is able to induce intra-tumour expression 
of T cell and NK cell-attracting chemokines CXCL9, CXCL10, and CCL5, which was 
associated with improved survival (Hong, Puaux et al. 2011). Therefore it will be 





Chapter 2: Ceramide, Acid-sphingomielinase and Tumour 
2.1 Lipids in cell signalling 
The high organization of biological systems involves communication between cells. 
The cells of a multi-cellular organism use released molecules to communicate with each 
other, and single-celled organisms respond to these messengers in their environment. 
Moreover, the organelles and the intracellular compartments inside the cell must 
communicate with each other. Among the molecules used in cellular communication, in 
the last  decade the attention has been focused on lipids. Cell membranes constitute lipid 
barriers that must be traversed by signal transduction pathways but membranes are also 
the source of the lipids involved in signal transduction. 
Membrane lipids participate as components of signal transduction pathways and as 
docking sites for cytoplasm signalling proteins, and they give rise to cleavage products 
that act as ligands or substrates for other signalling molecules. Non-membrane lipids have 
a role in signal transduction as well; lipids serve as ligands, and posttranslational lipid 
modifications provide a means for proteins to associate intimately with the membrane.  
The sphingolipids 
The role of lipids in cell signalling has been first suggested with the discovery of the 
phosphoinositides cycle (Berridge and Irvine 1984).The subsequent identification of other 
lipid second messengers and intracellular mediators such as the aracidonic acid, 
phosphatidic acid and phosphatidil-inositol 3,4,5 tridphosphate further confirmed the 
importance of lipid molecules in cell signalling.  
More recently another class of lipids has been identified as important signalling 
molecules: the sphingolipids.All sphingolipidsare composed by a long-chain sphingoid 
base backbone (e.g. sphingosine), an amide-linked, long-chain fatty acid and one of 
various polar head groups. The structure of these head groups defines the various classes 
of sphingolipid subtypes, with a hydroxyl group found in ceramide, phosphorylcholine in 
sphingomyelin (SM) and carbohydrates in glycosphingolipids. Sphingolipids are mainly 
present at the level of the plasma membrane, where they have a fundamental role in 
defining its physical and chemical properties. In addition to the structural role of the 
sphingolipids in the membrane bi-layer some of the intermediate molecules of its 
metabolism (ceramide, glucosyl-ceramide, and sphingosine-1-phosphate) have important 
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functions in cellular functions, such as growth, differentiation and apoptosis (Bleicher and 
Cabot 2002; Payne, Milstien et al. 2002; Hannun and Luberto 2004). 
The mechanisms of sphingolipid-mediated signal transduction are characterised by an 
extreme complexity (Riboni, Prinetti et al. 1995; Huwiler, Kolter et al. 2000). There are a 
number of metabolic processes, which regulate the levels of one type of sphingolipid. 
Furthermore there is a strict interaction between the different pathways, as for example 
the connection between ceramide and sphingosine-1-phosphate (S1P) metabolism(Van 
Brocklyn and Williams 2012).  
Enzymes in the sphingomyelin cycle 
Sphingomyelin is an important structural component of the cell membrane and of lipid 
rafts. It has an fundamental functional role as well as it is the parent compound of several 
lipid mediators (Figure 4) (Cremesti, Goni et al. 2002). Sphingomyelin is produced by 
sphingomyelin synthase (phosphatidylcholine/ceramide-PChtransferase) through the 
transfer of a phosphocholine head group from phosphatidylcholine to ceramide, after its 
transport to the cisternae of the Golgi. Sphingomyelin synthase is an integral membrane 
protein with membrane-bound ceramide and phosphatidylcholine as its substrates. The 
major site of sphingomyelin synthesis is not yet clear, because greater quantities of the 
enzyme reside in the plasma membrane than in the Golgi. However, the rate-limiting 
factor in the Golgi seems to be the availability of ceramide substrate. Inhibitors of 
glucosylceramide synthase stimulate synthesis of sphingomyelin, suggesting that 
sphingomyelin and ganglioside synthases compete for the same pool of substrate 
ceramide. An alternative pathway to the formation of sphingomyelin exists through the 
addition of phosphoethanolamine to ceramide followed by single methyl transfer to form 
the choline head group.  
The main component of sphingomyelin cycle is ceramide that can be synthesised either 
de novo by the sequential action of serine palmitoyltransferase, (dehydro) ceramide 
synthase, and (dehydro)- ceramidedesaturase, or through the breakdown of 
sphingomyelin by the activation of the catabolic enzymes sphingomyelinases. 
Sphingomyelinases are the most heavily studied enzymes in sphingolipid metabolism. 
Currently, five distinct enzymes have been identified based upon their pH optima, cellular 
localization, and cation dependence. The neutral membrane-bound Mg2+-independent 
sphingomyelinase (N-SMase) and the lysosomal acid pH optima sphingomyelinase (A-




An increase in N-SMase activity, a corresponding decrease in SM, and an increase in 
ceramide have been demonstrated in response to TNF, Fas ligand, 1α,25- 
dihydroxyvitamin D3,γ-interferon, chemotherapeutic agents, heat stress, 
ischemia/reperfusion, and interleukin-1 (Pettus, Chalfant et al. 2002). The factor 
associated with N-SMase activation (FAN) was recently identified as an adapter protein 
that associates with the intracellular domain of the TNF receptor, acting upstream of N-
SMase. In addition, both arachidonic acid and glutathione depletion have been shown to 
activate this enzyme. 




A-SMase was originally identified as a cation-independent hydrolase contributing to the 
catabolism of sphingomyelin in lysosomes, and responsible for the onset of Niemann–
Pick disease (NPD) (type A and B),determined by the deficiency of the enzyme that leads 
to lysosomal accumulation of Sphingomyelin (Horinouchi, Erlich et al. 1995). The 
enzyme is a 258 amino acid sequence that contains 11 cysteine residues at the C terminal, 
10 of which are forming disulphide bonds (C221-C226, C227-C250, C385-C431, C584-
C588, C594-C607), while at the N-activating terminal there are only 3 (C120-C131, C89-
C165, C92-C157) (Lansmann, Schuette et al. 2003)(Figure 5). At the N-terminus of the 
protein there is a signal peptide that directs the translation product into the endoplasmic 
reticulum (Hurwitz, Ferlinz et al. 1994). The murine enzyme has six potential N-
glycosylation sites, which prevent the enzyme form proteolytic degradation in the 
lysosome (Newrzella and Stoffel 1996). Additionally, A-SMase has a mannose 6-
phosphate (M6-P) residue that is required for lysosomal targeting of the enzyme via the 
M6-Preceptor (Newrzella and Stoffel 1992). However, recent studies have indicated that 
its localization is in fact not limited to the interior of lysosomes. Indeed, A-SMase is also 
secreted from vascular endothelial cells and macrophages through the Golgi secretory 
pathway, as a Zn2+-dependent enzyme (Marathe, Schissel et al. 1998). The Zn2+ 
dependency apparently results from the respective intracellular trafficking pathway; in the 
lysosomal pathway the enzyme is exposed to cellular pools of Zn2+ for full saturation, but 





Figure 8: A-SMase structure from (Lansmann, Schuette et al. 2003) 
 
 
The identified disulfide bond structure of haSMase is presented. The N-terminus of native 
haSMase from human placenta is Gly83  referring to the open reading frame of the 
haSMase-cDNA (His60: N-terminus of mature bc-haSMase expressed in SF21 cells using 
the baculovirus expression vector system. Contrary to position N503 in the native human 
protein, glycosylation site N503 of bc-haSMase is glycosylated. 
Studies carried out in COS-1 cells transfected with A-SMasecDNA, have identified three 
major forms of the protein of 75, 72, and 57 kDa that are generated from the same nascent 
polypeptide derived from a single processed transcript (Ferlinz, Hurwitz et al. 1994). 
After deglycosilation they are reduced in size of 64, 61 and 47 kDa respectively. The 75 
kDa form is the prepolypeptide, which is found in the endoplasmic reticulum. The second 
form is considered the enzyme precursor and is obtained by cutting a possible signalling 
sequence of 4 kDa. The 72 kDa precursor is then transported to the endo/lysosomal 
compartments (Hurwitz, Ferlinz et al. 1994) where it is processed to its mature form of 70 
kDa. The mature enzyme is degraded to an inactive form of 52 kDa. 
When, upon stimulation, A-SMase is relocated from intracellular organelles to the outer 
leaflet of the plasma membrane, it plays a central role in the hydrolysis of SM localized 
within lipid raft microdomains, that are formed by dynamic clustering of sphingolipids 
and cholesterol and function as platforms for signal transduction and protein sorting 
(Simons and Ikonen 1997). Cell surface lipid microdomains are thought to be specific 
sites for Cer generation in response to various agonists and stress signals. Grassme et al. 




SMase from intracellular compartments to the outer leaflet of the plasma membrane, and 
that Cer generation by the A-SMase within lipid microdomains is essential for CD95 
signalling and the induction of apoptosis (Grassme, Jekle et al. 2001; Perrotta, Bizzozero 
et al. 2010).Cer provides the driving force for the coalescence of lipid microdomains into 
larger platforms and the subsequent induction of CD95 clustering and oligomerization of 
the downstream effectors FADD and pro-caspase-8, events required for transmission of 
the CD95 death signal (Grassme, Jekle et al. 2001)(Figure 6). Furthermore, this signalling 
model is not restricted to CD95, as A-SMase on the cell surface is essential for the 
clustering of CD40 (Grassme, Jendrossek et al. 2002), Fcγ receptor II (Abdel Shakor, 
Kwiatkowska et al. 2004), CD20, and TRAIL receptor (Martin, Phillips et al. 2005). 
Figure 6. Acid sphingomyelinase activation, adapted from (Grassme, Jekle et al. 2001). 
A-SMase and ceramide-mediated receptor clustering in membrane platforms functions as a prerequisite for 
receptor signalling. Stimulation via CD95  activates A-SMase and triggers a translocation of the enzyme 
onto the cell surface. The release of ceramide in small rafts correlates with the fusion of these small 
membrane domains to large platforms and the trapping of receptor molecules within ceramide-enriched 
membrane platforms. 
2.2 Sphingolipids in tumours 
Many sphingolipid-regulated functions have significant and specific links to various 
aspects of cancer initiation, progression and response to anticancer treatments. Ceramide 
in particular is intimately involved in the regulation of cancer-cell growth, differentiation, 
senescence and apoptosis (Hannun 1996; Hannun and Obeid 2002). Many cytokines, 
Introduction 
37 
anticancer drugs and other stress-causing agonists result in the increase in endogenous 
levels of ceramide through de novo synthesis and/or the hydrolysis of sphingomyelin. 
Reciprocally, decreased levels of endogenous ceramide caused by increased expression of 
glucosylceramide synthase (GCS), which clears ceramide levels by incorporating it into 
glucosylceramide, results in the development of a multidrug resistance phenotype in 
many cancer cells(Liu, Han et al. 2001). 
In contrast to the actions of ceramide, S1P is emerging as a key regulator of proliferation, 
inflammation, vasculogenesis and resistance to apoptotic cell death(Payne, Milstien et al. 
2002). Many growth factors and cytokines activate sphingosine kinase, and so lead to 
transient increases in S1P levels. S1P is then secreted from the cell and acts either in a 
paracrine or an autocrine manner to engage specific transmembrane hepta-helical G-
protein-coupled receptors, termed S1P receptors (S1PRs), which were formerly known as 
the endothelial differentiation gene receptors (Hla 2003). Activation of S1PRs mediates 
signalling pathways that predominately result in increased cell motility and 
proliferation(Hla 2003). In addition, several studies indicate a non-receptor, intracellular 
action of S1P(Payne, Milstien et al. 2002), although the direct target remains elusive. S1P 
also exerts pro-survival functions that derive, at least in part, from its role in activating 
the transcription factor NF-κB(Maceyka, Payne et al. 2002)and the induction of COX-2 
and its pro-survival prostaglandin products (Pettus, Bielawski et al. 2003). The regulation 
of COX-2 and NF-κB by S1P is important in tumourigenesis, and both of these proteins 
are activated in various human malignancies. 
Ceramide in tumours 
ful tumour suppressor, potentiating signalling events that drive 
ribed the role of ceramide in the extrinsic apoptosis pathway, 
Ceramide is a power
apoptosis, autophagic responses and cell cycle arrest, thus its metabolism is tightly 
regulated in cancer cells. In order to survive, cancer cells upregulate the enzymes that 
metabolise ceramide, thus resulting in apoptotic responses and/or in the promotion of 
mitogenicity, depending on the routes by which ceramide is metabolised (Morad and 
Cabot 2013) (Figure 7). 
Many papers have desc
which begins outside the cell via the engagement of pro-apoptotic receptors, as CD95, 
TRAILRs and TNFR1, on the cell surface. Activation of these receptors increases 
ceramide levels at the plasma membrane and in the nucleus through the activation of 
SMase and leads to caspase activation and apoptosis (Cai, Bettaieb et al. 1997; Colell, 
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Morales et al. 2002; Huang, Yang et al. 2004; Dumitru and Gulbins 2006; Park, Zhang et 
al. 2008; Park, Mitchell et al. 2010). Cancer cells have developed several mechanisms to 
overcome this signalling cascade. Low levels of intracellular ceramide are associated with 
resistance to: TRAIL-induced death in breast (Zhang, Yoshida et al. 2009)and colon 
cancer cells (Voelkel-Johnson, Hannun et al. 2005; White-Gilbertson, Mullen et al. 2009), 
as well as in human renal carcinoma cells (Asakuma, Sumitomo et al. 2003); and TNF-
induced apoptosis in breast cancer and hepatoma cells (Cai, Bettaieb et al. 1997; Liu, Han 
et al. 1999; Autelli, Ullio et al. 2009). 
As the failure of cancer chemotherapy partly arises from resistance to death receptor 
an induce 
he consequences of this union 
ll survival and cell death. On the survival 
signalling pathways, therapeutic ceramide should be considered as an adjuvant therapy 
with drugs that target the TNF receptor superfamily (Morad and Cabot 2013). 
Ceramide is also involved in the intrinsic apoptotic pathway as it c
mitochondrial outer membrane permeabilization (MOMP), a key event in apoptotis, 
through the formation of ceramide channels (Morad, Levin et al. 2012).Another way that 
ceramide affects mitochondrial function is by inducing the translocation to the 
mitochondria and the activation of protein kinase Cδ (PKCδ), which in turn promotes 
cytochrome c release and caspase 9 activation, as shown in prostate cancer 
cells(Sumitomo, Ohba et al. 2002).From the above, we should state that ceramide–
mitochondria interplay is an important, but complicated, aspect of cancer biology. Of 
importance, it is the role of N-SMaseandA-SMase, as well as Ceramide Synthases 
(CERSs), to present ceramide for the initiation of mitochondrial-directed apoptotic 
responses. These enzymatic events are often deregulated in cancer in a cell-type specific 
manner, meaning that some phenotypes might harbour suppressed CERS activity, 
whereas others might overexpress GCS to decrease ceramide levels. The overexpression 
of GCS is particularly relevant to multidrug-resistant cancer(Liu, Han et al. 1999; 
Senchenkov, Litvak et al. 2001; Bleicher and Cabot 2002). 
This relationship between ceramide and mitochondria and t
highlight the appeal of ceramide as a therapeutic agent that can shutdown cancer cell 
resistance to the intrinsic apoptotic pathway. 
Autophagy regulates the balance between ce
side, autophagy eliminates damaged proteins and organelles and maintains cellular 
homeostasis. On the cell death side, autophagy has a tumour suppressive role. However, 
in established cancers, tumour cells can use autophagy as a survival mechanism in 
response to chemotherapeutic or nutritional stress. Therefore, the induction of autophagy 
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by dihydroceramide and ceramide in cancer cells is not necessarily a good thing, unless it 
can be manipulated to induce apoptosis (Morad and Cabot 2013). 
In various cancer models, dihydroceramide and ceramide trigger autophagy by eliciting 
king AKT 
cellular starvation through the downregulation of nutrient transporter proteins, leading 
also to the downregulation of the activity of mTOR, one of the most important players in 
autophagy (Guenther, Peralta et al. 2008; Pattingre, Bauvy et al. 2009; Pozuelo-Rubio 
2011). Moreover, ceramide and dihydroceramide can block mTOR activity by inhibiting 
one of its regulator, phospholipase D (PLD )(Venable, Bielawska et al. 1996). 
Ceramide has been shown to inhibit mTOR, leading to autophagy, by bloc
(Scarlatti, Bauvy et al. 2004),by activating AMP-dependent protein kinase (AMPK) 
(Peralta and Edinger 2009; Kim, Kundu et al. 2011), another upstream regulator of 
mTOR, and finally by the promotion of BNIP3 transcription(Daido, Kanzawa et al. 
2004). 
Finally, ceramideis also involved in cell cycle arrest through different mechanisms: by 
affecting an increase in p21 association with Cyclin-dependent kinase 2 (CDK2)and by 
activation of protein phosphatases that selectively inhibit CDK2 (Lee, Bielawska et al. 
2000); by increasing the expression of p21 in a p53-dependent manner (p21 expression is 
induced by p53 ) (Struckhoff, Patel et al. 2010)and in a p53-independent manner 
(Pruschy, Resch et al. 1999; Kim, Kang et al. 2000), thus leading to G1 arrest; by 
suppressing survivin expression (Ahn and Schroeder 2010; Lechler, Renkawitz et al. 
2011), and survivin is a key regulator of mitosis that is involved in regulating the G2/M 
transition (Lechler, Renkawitz et al. 2011). 
Taking into account that the deregulation of molecular events governing the cell cycle is a 
hallmark of cancer and is a central issue in cancer progression, the control of cell cycle 
regulatory molecules by ceramide is one means of facing cancer progression and 
tumourigenesis, and of limiting drug resistance. 
Introduction 
Figure 7: Roles of ceramide/sphingosine-1-phosphate in specific cancers (Ogretmen and 
Hannun 2004) 
Levels of the candidate tumour-suppressor lipid ceramide are altered in various solid tumours, whereas the 
levels of the tumour promoting lipid sphingosine-1-phosphate (S1P) are increased in colon cancers and 
leukaemias. The red arrows show the sphingolipid pro-survival, tumourigenic and chemotherapy-resistance 
pathways that have been identified in tumours. In colon cancers, induction of sphingosine kinase 1 (SK1) 
results in the accumulation of S1P, possibly leading to neovascularization and inflammation. In breast 
cancer cells, attenuation of ceramide levels by the action of glucosylceramide synthase (GCS), which 
converts ceramide to glucosylceramide (GlcCer), results in the development of drug resistance. Expression 
of P-glycoprotein (P-gp) might exacerbate this situation, where as inhibition of GCS reverses drug 
resistance.  
CDase, ceramidase; ER, endoplasmic reticulum; PP1, protein phosphatase 1; PP2A,protein phosphatase 2A; 
GSL, glycosphingolipid. 
Acid Sphingomyelinase in tumours 
The link between cancer, A-SMase, and ceramide has been extensively studied. For 
example, decreased ceramide has been reported in astrocytomas, ovarian, lung, and other 
cancers (Rylova, Somova et al. 1998; Selzner, Bielawska et al. 2001; Riboni, Campanella 
et al. 2002; Ogretmen and Hannun 2004).In addition, an inverse relationship has been 
found between ceramide levels and glioma stratification into high- and low-grade 
tumours (Riboni, Campanella et al. 2002). Of interest, an analysis of the microarray 
database Oncomine (www.oncomine.org, January 3, 2008) revealed that 12/104 matched 
cancer vs. normal tissue comparisons underexpressed the A-SMase mRNA (P<0.0005), 
with 4/104 comparisons that overexpressed it. In 104 comparisons with a Bonferroni 
corrected threshold for significance of P< 0.0005, five false positives are expected. This 
would predict that in at least some cancers A-SMase may be down-regulated, contributing 
to their reduced ceramide content and perhaps directing the cells away from apoptosis and 
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toward proliferation. Down-regulation of A-SMase and ceramide production also may 
play a role in drug resistance(Smith and Schuchman 2008). 
In addition to these observations, many publications have shown that A-SMase is 
important in the response of cancer cells to a variety of antineoplastic treatments. For 
example, in the Fas-induced apoptotic response of glioma cells, A-SMase was shown to 
be activated, and its inhibition caused a Fas-resistant phenotype(Sawada, Nakashima et al. 
2002; Perrotta, Bizzozero et al. 2010). Paclitaxel-induced apoptosis of human ovarian 
carcinoma cells also was found to be mediated by A-SMase-generated ceramide, and cells 
conditioned to be paclitaxel resistant were characterised by their lack of ceramide 
generation after treatment (Prinetti, Millimaggi et al. 2006). Cisplatin treatment of colon 
cancer cells was similarly shown to induce activation of A-SMase, changes in membrane 
fluidity, clustering of CD95, and ultimately apoptosis. Pharmacologic inhibition of A-
SMase decreased membrane changes, CD95 clustering, and apoptosis (Lacour, Hammann 
et al. 2004). More recently, thesame group has demonstrated that changes in the Na+/H+ 
transporter activity (NHE1) after cisplatin treatment of these cells is responsible for 
acidification, contributing to A-SMase activation at the cell surface and the apoptotic 
response (Rebillard, Tekpli et al. 2007).In addition, the apoptotic response of 
neuroblastoma cells to fenretinide was ameliorated by A-SMase targeted siRNA but not 
by scrambled siRNA (Lovat, Di Sano et al. 2004). Thus, ASM is involved in the response 
of many cancers to antioncogenic treatments. Although all of these cancer treatments 
have other “known” mechanisms of action (e.g., DNA damage, disruption of microtubule 
assembly,etc.), it is becoming increasingly clear through work on sphingolipids and in 
other fields that secondary cell membrane changes play an important part in the action of 
these compounds. Clearly, A-SMase is an important component of this process. 
In addition to the role that A-SMase plays in cancer cells themselves, researchers are also 
becoming aware of its importance in the tumour microenvironment, and some data have 
been published regarding its role in angiogenesis. It is well known that solid tumours 
cannot grow beyond a certain size without the recruitment of a vascular supply, and the 
development of antiangiogenetic cancer treatments is an extremely active area of 
research. The microvasculature of the small intestine relies on A-SMase for irradiation-
induced apoptosis (Paris, Fuks et al. 2001). Endothelial cell death after irradiation in the 
Central Nervous System (CNS) was also found to be dependent on A-SMase through 
analysis of A-SMase KO mice(Pena, Fuks et al. 2000; Li, Chen et al. 2003). Perhaps the 
most interesting and substantial finding linking A-SMase to angiogenesis came from a 
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2003 study by Garcia-Barros et al. (Garcia-Barros, Paris et al. 2003)where, identical 
tumours were established in either wild-type or A-SMase KO mice and then irradiated, 
and it was shown that the tumour response to irradiation was dependent on the A-SMase 
status of the recipient mouse.  
All these evidences highlight the key role of A-SMase in tumour development and in 
response to chemotherapeutics whenever it is expressed by host or tumour cells.. It is not 
still clear in particular how the host effect of A-SMase are mediated and possible roles 
have been proposed not only for the endothelium (Garcia-Barros, Paris et al. 2003)but 
also for the host immune system. Indeed, previous studies, including some in the B16 
melanoma model in vivo, indicate that A-SMase is a key determinant in the function of 
immune cells, regulating not only their sensitivity to apoptosis but also their 
differentiation and response to inflammatory/differentiative stimuli (Sciorati, Rovere et 
al. 1997; Paolucci, Rovere et al. 2000; Paolucci, Burastero et al. 2003; Falcone, Perrotta 
et al. 2004; Perrotta, Bizzozero et al. 2007). The function and mechanisms of action of A-
SMase in host vs. tumour interactions have not been elucidated: a thorough elucidation of 
these aspects may lead to identification of novel relevant molecular players and hence to 
significant advances in the identification of possible new therapeutic strategies to cancer 
therapy. 
Ceramide and Acid Sphingomyelinase in Cancer Therapeutics 
Recently, modulating the ceramide pathway by various approaches has been shown to 
successfully inhibit cancer growth both in vivo and in vitro. One example is through the 
inhibition of an enzyme that degrades ceramide, acid ceramidase (AC). Systemic 
administration of AC inhibitors has been shown to inhibit xenograph growth of both head 
and neck squamous cell carcinomas (Elojeimy, Liu et al. 2007) and hepatomas (Morales, 
Paris et al. 2007) in mice. Grammatikos et al. showed for the first time that transfection of 
the A-SMase cDNA into murine glioma cells can sensitize them to the chemotherapy 
agents doxorubicin and gemcitabine (Grammatikos, Teichgraber et al. 2007). Most 
recently overexpression of A-SMase has been shown to enhances the antineoplastic 
effects of irradiation in vitro and in vivo (Smith and Schuchman 2008). Moreover Savic et 
al. demonstrated that rhASM/sorafenib combination exhibited a synergistic effect on 
reducing the tumour volume and blood vessel density in Huh7 xenografts, despite modest 
activity of rhASM in these tumours, despite no significant increases in survival were 




All these evidences suggest a possible and particularly intriguing use of A-SMase as an 
antioncogenic drug, even because preclinical studies performed for the development of 
NPD enzyme replacement therapy have shown that it can be administered at high doses 
into normal animals without deleterious effect. In addition, the acidic pH optimum of the 
enzyme favours its preferential activity within the acidic microenvironment of tumours. 
Good Manufacturing Practice (GMP)-approved recombinant A-SMase has already been 
manufactured and is currently being evaluated in clinical trials as a treatment for type B 
NPD. 
Aim of Study 
AIM OF THE STUDY 
The aim of this study is the investigation of the role of Acid Sphingomyelinase (A-
SMase) expressed by cancer cells in host versus tumour interactions, in particular 
dissecting the possibility that a different expression of this enzyme is related to 
modification in the extent and type of tumour microenvironment, with the purpose to 
consider A-SMase as an adjuvant for cancer therapy. To this end we characterised in vivo 
the connection between A-SMase expression and the composition of tumour 
microenvironment. 
All the in vitro and In vivo experiments were performed using the murine melanoma 
model and C57/BL6J mice. 
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Materials 
The following reagents were purchased as indicated: the Malignant melanoma, metastatic 
malignant melanoma and benign nevus tissue array ME1003, the Lung disease spectrum 
tissue array BC04002, the Colon cancer tissue array CO1503, the Adrenal gland disease 
spectrum (adrenal cancer progression) tissue array AD2081,from US Biomax, Inc.; the 
polyclonal antibody (Ab) against A-SMase from Areta international; the polyclonal Ab 
against CD11b, Gr1 from MiltenyiBiotec; the polyclonal Ab against F4/80 from 
BioLegend; the polyclonal Ab against CD80, CD86, CD11c, MHCII, Cd4, CD8, CD44, 
CD25, Foxp3 from eBiosciences; the polyclonal Abs against MycTagand the anti-rabbit 
Ab HRP-conjugated from Cell Signaling Technology; Clarity Western Blotting ECL 
substrate from Bio.Rad. Reagents for cell cultures were from Euroclone; Bicinchoninic 
Acid kit from Thermo Scientific; Spmd1siRNAs, pSilencer4.1-CMV neo kit and the 
scrambled controls siRNA, goat Alexa Fluor 546, LipofectamineRNAiMAX Transfection 
Reagent, pEF1/Myc plasmid, Trizol Reagents from Life Technologies; Fugene 
Transfection Reagent from Roche; RNeasy Micro kit from Qiagen; ImProm-II™ Reverse 
Transcription System from Promega; all other reagents from Sigma-Aldrich. 
Methods 
Animals 
Female C57BL/6J mice (6–8 weeks old) were purchase by Charles River (Wilmington, 
MA, USA) and treated in accordance with the European Community guidelines and with 
the approval of the Institutional Ethical Committee. 
Cell Culture and Treatments 
MC38 murine colon cancer and LLC murine Lewis lung carcinoma cell lines were 
cultured in DMEM supplemented with 10% heat-inactivated FBS, glutamine (200 mM), 
penicillin/streptavidin (100 U/ml), pH 7.4, 3T3 mouse fibroblasts, H5V mouse 
endothelial cells, B16-F1 mouse melanoma cell line and all B16 subclones were cultured 
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in Iscove’s supplemented with 10% heat-inactivated FBS, glutamine (200 mM), 
penicillin/streptavidin (100 U/ml), 1% Hepes 1M pH 7.4. Cells were grown at 37 °C in a 
humidified atmosphere containing 5% CO2. 
Immunofluorescence of Human Tissue Arrays 
The tissue arrays were deparaffinized by two xylene rinses of 30 minutes each followed 
by two rinses with 100% ethanol for 1 minute each and a rinse in water. Antigen retrieval 
was done by boiling the slides in a pressure cooker in a sodium citrate buffer at a pH of 
6.0. After rinsing briefly in 1xPBS, a 10 minute incubation with 0.1M glycine-PBS was 
used to quench tissues autofluorescence. To reduce nonspecific background staining, 
slides were incubated with 4% bovine serum albumin/1× PBS for 1 hour at room 
temperature. After permeabilization with 1xPBS/1% Triton,  slides were incubated 
overnight at 4°C with with specific antibody for A-SMase in 4% BSA/1xPBS. For 
fluorescent detection appropriate secondary antibody conjugated with Alexa 546 (red) 
was used. Slides were examined using a Leica DMI4000 B automated inverted 
microscope equipped with a DCF310 digital camera (Leica Microscopy Systems, 
Heerbrugg, Switzerland). Image acquisition was controlled by the Leica LAS AF 
software. 
Immunofluorescence quantification 
Immunofluorescence was quantified with MacBiophotonics Image J. The RGB images 
were splitted to the respective red, green and blue image components. The red images 
were processed separately. By using five random test samples stained for every primary 
antibody, suitable threshold levels red were determined and kept constant for all analysis. 
Thresholding creates binary red positive masks in which red-positive pixels are pseudo-
coloured with black, while the background is indicated with white colour. The extent of 
staining is calculated as integrated optical density (IOD), which is equal to the area × 
average density of image occupied by immunoreactivity(Konsti, Lundin et al. 2011) and 
represented in graph as the mean ± SEM. 
To verify the reproducibility of the analysis, two blinded operators performed the same 
measurements for Human Melanoma Tissue Arrays using also the computer-assisted 
imaging analysis AxioVision Rel.4.6 (Carl Zeiss) (Kashani-Sabet, Rangel et al. 2009). 
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Analysis of A-SMase in murine tumours 
On day 0, C57BL/6 mice received 5 × 104 B16-F1 cells, 2 × 105 LLC cells 
subcutaneously (s.c.) in the lower-right flank; and 2,5 × 104 MC38 cells intraperitoneally 
(i.p.). 
Mice were sacrificed and tumour collected when they reached 5×5×3 mm and 10×10×8 
mm for each diameters for B16-F1, RMA and LLC-derived  tumours, and at day 7 and 
day 15 after injection for MC3-derived ones. A-SMase expression was then evaluated by 
quantitative real time PCR (qPCR) 
Reverse Transcription-PCR and Quantitative Real Time-PCR (qPCR) 
Total RNA from cells and tissues was extracted with the High Pure RNA Isolation Kit 
and High Pure RNA Tissue Kit (Roche), according to the manufacturer’s recommended 
procedure. After solubilization in RNase-free water, total RNA was quantified by the 
Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific). First-strand cDNA was 
generated from 1 μg of total RNA using ImProm-II Reverse Transcription System 
(Promega).  
qPCRwas performed using LightCycler 480 SYBR Green I Master (Roche) on Roche 
LightCycler 480 Instrument, according to manufacturer’s recommended procedure. As 
shown in Table below, a set of primer pairs were designed to hybridize to unique regions 
of the appropriate gene sequence. All reactions were run as triplicates. The melt-curve 
analysis was performed at the end of each experiment to verify that a single product per 
primer pair was amplified. As to control experiments, gel electrophoresis was also 
performed to verify the specificity and size of the amplified qPCR products. Samples 
were analysed using the Roche LightCycler 480 Software (release 1.5.0) and the second 
derivative maximum method. The fold increase or decrease was determined relative to a 
control after normalizing to GAPDH (internal standard) through the use of the formula 2-
ΔΔCT(Livak and Schmittgen 2001; Schefe, Lehmann et al. 2006). 
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B16-W6_pSIL10 and B16-F1_B1A cell line generation 
Two stable transfected cell lines expressing respectively a shRNA sequence silencing 
ASMase expression and pEF1/Myc vector containing cDNA for A-SMase were generated 
from B16 F1 cell line. 
Transfection of the shRNA vector was performed in B16-F1 cells using Fugene 
transfection reagent. Briefly, cells seeded in 100-mm petri dish one day prior to 
transfection. were transfected with 5 μg vector DNA at 30-40% confluence. After 36 hour 
incubation in the appropriate growth medium, cells were splitted at 40% confluence in 
medium containing 500 μg/ml of G418, previously identified as the optimal antibiotic 
concentration for the seclection, and selection was performed for 7-10 days. 
Approximately 30 resistant cell colonies were tested for A-SMase silencing through 
FACS analysis. The selected clone (clone B16-W6_psil10) showed the highest decrease 
in A-SMase expression comparing to the control cell line (Figure 1). 
Transfection of the plasmide pEF1/Myc containing A-SMase cDNA was performed in 
B16-F1 cells using Fugene transfection reagent according to the manufacturer’s protocol. 
Approximately 20 colonies resistant to the antibiotic G418 (500 µg/ml) were tested for 
Myc expression through WB analysis and only 5 showed positivity to it (Figure 2B). 
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Among this five clones, we chose B1A which showed the highest increase in A-SMase 
expression both at mRNA (Figure 2A) and protein (Figure 2B) levels comparing to B16-
F1 mock transfected cell line. Of importance, this clone also showed the highest A-SMase 













Figure 1: B16-W6_pSIL colonies A-SMase expression screening 
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Figure 2: Stably trasfection with A-SMase accounts for higher protein expression and 
activity in B16-F1 clones.  
qPCR analysis of A-SMase expression in B16-F1_pEF1 and different clones(A). Values are expressed as 
fold change over control (ctr) (n = 3). Western blotting analysis of A-SMase on cell lysates. The graph 
shows the densitometric values normalized on TBP. Values are expressed as fold change over control (ctr) 
(n = 3) (B). A-SMase activity on cell lysates measured as sphingomyelin hydrolysis to phosphorylcholine at 
pH 5.5. Values are expressed as fold change over control (ctr) (n = 3) (C). 
Asterisks indicate statistical significance vscontrol (mock-trasfected B16-F1 cells). *p < 0.05; ***p < 0.001. 
Western blotting 
Cells were washed twice with ice cold PBS lysed in RIPA lysis buffer (50mM Tris-HCl 
pH 7.4, 150mM NaCl, 1% NP40, 0.25% Na-deoxycholate) containing a cocktail of 
proteases and phosphatases inhibitors. After 30 min of incubation on ice, the cell lysates 
were centrifuged 5 min at 1500 x g in order to pellet cell debris and the supernatant was 
transferred into new tubes. 
Protein separation was performed following the standard protocol for western blotting. 
Samples were solubilized in Laemmli buffer, boiled 5 min at 100 °C. and loaded on g 7,5 
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% polyacrylamide precast gels (Mini-PROTEAN TGXTM; Bio-Rad) immersed in running 
buffer (Tris-base, SDS, glycin) (Gels were run at 300V). Proteins separated in the gel 
were transferred onto a nitrocellulose membrane using a Bio-Rad's Trans-Blot Turbo 
SystemTM (7 min at 2.5 A) using Bio-Rad Transfer packTM . 
The nitrocellulose membrane was blotted with Ponceau red, to determine the quality of 
the protein transfer. Then it was incubated for 1 hour at room temperature in a blocking 
buffer (TBS-T: Tris-buffered saline-Tween 20 (Tris-HCl, NaCl, Tween 20) and non fat 
dry milk 5%), to block the sites for unspecific binding of the antibodies to the membrane. 
Then, membrane was incubated with a primary antibody, specific for the protein of 
interest, and, after three washes in TBS-T, with a secondary anti-rabbit horseradish 
peroxidase (HRP)-conjugated antibody, both diluted in Blocking buffer for 1 hour each. 
After these incubations the membrane was rinsed with TBS-T 3x10 min. Detection of the 
antigen was performed with the system of HRP/Hydrogen Peroxide catalyzed oxidation 
of luminol in alkaline conditions using the Clarity Western ECL Substrate by Bio-Rad. 
The light produced by this enhanced chemiluminescent reaction was detected using 
CemiDocMP Imaging SystemTM. 
Acid sphingomyelinase activity 
A-SMase activity was determined by measuring conversion of sphingomyelin to 
phosphorylcholine in cell homogenates using the Amplex Red Sphingomyelinase Assay 
Kit according to the two step standard protocol. In brief, 2 x 106 cells were homogenated 
with 0.2% Triton-X100 in H2O for 15 minutes at 4°C, sonicated, and incubated overnight 
at 80°C. For enzymatic activity assay 100 μg of homogenate from each sample were 
diluited in 100 μl50 mM sodium acetate, pH 5.0 and plated in a 96 well microplate. 
Similarly a negative control without the enzyme were set up. The first step reaction was 
started adding 10 μl of the 5 mMsphingomyelin solution to samples or negative control 
and incubated at 37°C for 1 hour. At this point two positive controls were prepared 
diluiting sphingomyelinase from bacillus cereus at the final concentration of 4 U/ml and 
H2O2 10 μM in 100 μl of 1x reaction buffer and adding 10μl of the 5 mM sphingomyelin 
solution. The second step reaction were performed adding to samples, and negative and 
positive controls, 100 μL of the Amplex Red reagent containing 2 U/mL HRP, 0.2 U/mL 
choline oxidase and 8 U/mL alkaline phosphatase and incubated for 30 minutes at 37°C, 
protected from light. The fluorescence were measured in a fluorescence microplate reader 
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using excitation in the range of 530–560 nm and emission detection at ~590 nm. For each 
point, background fluorescence was corrected by subtracting the values derived from the 
no-sphingomyelinase control. 
Flow Cytometric Analysis of Tumours 
For flow cytometric analysis, tumours were removed from euthanized mice, smashed, 
filtered through a 70-μm filter, and washed twice with 1x PBS. After erythrocyte lysis, Fc 
receptors were blocked with 1% BSA in 1xPBS for 30 min at 4°C. After one wash with 
PBS, cells were incubated for 15 min at room temperature with appropriate antibodies 
(CD4, CD8, CD25, CD44, Foxp3, CD11b, GR1, F4/80, CD11c, CD80, CD86, MHCII). 
Samples then were washed and resuspended in PBS. Samples were acquired using a 
Fluorescence-Activated Cell Sorter (FACS) (FC500 Dual Laser system Beckman Coulter, 
Brea, CA, USA) and analysed using FCS Express 4 Flow Research Edition software. 
Bone marrow derived macrophage cells preparation 
Bone marrow cell suspensions were isolated by flushing femurs and tibias of 8- to 12-
week-old C57Bl/6 mice with complete MEM alpha (+10% FBS, +1% Pen/Strep, +1%l-
glutamine). Aggregates were dislodged by gentle pipetting, and debris was removed by 
passaging the suspension through a 40-µm nylon cell strainer. Cells were washed twice 
with medium, and seeded on ultra-low attachment surface plates. Cells were cultured in 
with complete MEM alpha (+10% FBS, +1% Pen/Strep, +1%l-glutamine) supplemented 
with 100 ng/mL rhM-CSF and cultured in a humidified incubator at 37C and 5% CO2 for 
7 days. On days 3 and 5 cells were amplified and medium was refreshed. 
Transwell Co-cultures of B16-F1 Melanoma/macrophages 
Bone marrow derived macrophages (2 × 106) were plated on the upper compartment of 
0.4-μm pore size transwell plates (Costar) in 0.1 ml of ISCOVE complete medium, while 
B16-F1 melanoma cells (0.3 × 106 in 0.6 ml) were placed on the lower chamber. Co-
cultures were incubated for 24 hours at 37°C and 5%CO2, after which B16 cells were 
harvested and total RNA was extracted. Samples were then assayed for A-SMase 
expression by qRT-PCR. 
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Tumour growth in vivo 
C57BL/6 mice (ten animals per group) received 5 × 104B16-F1_pEF1 and B16-F1_B1A 
cells s.c. in the lower-right flank on day 0. 
Tumor growth was monitored twice a week by a caliper. Mice were sacrificed when their 
tumours reached 15 mm on either diameter. 
Statistical analysis 
Upon verification of normal distribution, statistical significance of raw data between the 
groups in each experiment was evaluated using unpaired the Student’s t-test or ANOVA 
followed by the Bonferroni post-test. Kaplan-Meyer data were analysed with the multiple 
comparison survival curve method using the Log-rank (Mantel-Cox) test.Results are 
expressed as means ± standard error of the mean (SEM). 
Results 
RESULTS 
Acid sphingomyelinase decreases during tumour progression in different human 
cancers 
A-SMase plays a key role in tumour progression and in mediating responses to 
chemotherapeutics (Smith and Schuchman 2008), thus we decided to analyse its 
expression in different human cancers. 
A-SMase expression was evaluated by immunofluorescence in histological sections from 
human bioptic specimens of different tumours at various stages (melanoma tissue array). 
Interestingly, in tumours from skin, adrenal gland, lung and colonwe found an inverse 
correlation between tumour progression and A-SMase expression (Figure 1A-D). 
Quantitative analyses of results from several samples carried out using ImageJ as analysis 
software, indicate that the differences in A-SMase expression between the groups of 










Immunofluorescence staining of human tumours from skin (A, upper panels), adrenal gland (B, upper 
panels), lung C, upper panels) and colon (D, upper panels) at different stages with A-SMase antibody 
(scale bar, 110 µm). 
Quantitative assessment of immunofluorescence staining of A-SMase on human samples from skin 
(malignant melanoma, n=26; lymph node metastasis, n=13) (A, lower panel), adrenal gland 
(pheochromocytoma, n=29; adrenal cortex adenoma, n=36; adrenal cortex adenocarcinoma, n=10) (B, 
lower panel), lung ( lung tumours, n=59; lymph node metastasis n=7) (C, lower panel), colon (T3 colon 
tumours, n=38; T4 colon tumours n=50) (D, lower panel). Values in the graphs are expressed as mean ± 
SEM. 
Asterisks indicate statistical significance ,*p< 0.05; ***p < 0.001. 
Acid sphingomyelinase decreases during tumour progression in different murine 
cancers 
To assess whether the same variability in A-SMase expression during tumour progression 
occurs also in mouse, we analysed its expression in different in vivo model of murine 
tumours: MC38, colon carcinoma, , Lewis lung carcinoma (LLC), and B16-F1melanoma. 
To this end, C57B/L6 female mice were s.c.with5 × 104B16-F1 cells, 1 × 105 RMA cells 
and 2 ×105 LLC cells and i.p. with 2,5 × 104 MC38 cells.  
Mice were sacrificed and tumour collected when they reached 5×5×3 mm (here referred 
to as early stage) and 10×10×8 mm (here referred to as late stage) for each diameters for 
B16-F1, RMA and LLC tumours, and at day 7 (early stage) and day 15 (late stage) after 
injection for MC38 ones. 
We analysed these samples for A-SMase expression (mRNA) by qPCR and we observed 
that only in B16-F1 and MC38-derived tumours it decreased significantly during tumour 
progression (Figure 2A and B). 
Taken together these data indicate that in some tumours, both in human and in mouse, 
there is an inverse correlation between A-SMase expression and tumour malignancy. 
Moreover, the regulation of A-SMase levels is transcriptional, as indicated by the 
decrease not only of the protein expression (Figure 1) but also of its mRNA (Figure 2A 
and B).  
These results prompted us to investigate the mechanisms responsible of this event and 
their biological consequences. We decided to study this phenomenon using the B16-





Figure 2:Acid sphingomyelinase decreases during tumour progression in different murine 
cancers 
qPCR analysis of A-SMase expression in B16-F1 (A) (early, n=12, late, n=16), MC38 (early, n=10; late, 
n=11) (B) and LLC (early, n=7; late, n=6) (C) -derived tumours at different stages of progression. Values 
are expressed as fold change ± SEM. 




Acid sphingomyelinase downregulation in melanoma could be driven by immune 
cells-released factors 
In our previous work we have demonstrated that A-SMase downregulation during 
melanoma progression favours tumour growth conferring a more aggressive behaviour to 
melanoma cells both in vivo and in vitro (Bizzozero, Cazzato et al. 2013). Thus we 
decided to investigate the mechanisms responsible for this decrease. 
In the last decades, it has been largely shown that a complex cross-talk exists between 
tumour cells and its immunological microenvironment (Yu, Kortylewski et al. 2007; 
Mattei, Schiavoni et al. 2012; Businaro, De Ninno et al. 2013; Schiavoni, Gabriele et al. 
2013). Moreover, it has been demonstrated that citokynes released by the tumour infiltrate 
are able to induce molecular changes in tumour cells (Kanterman, Sade-Feldman et al. 
2012), leading us to hypothesise a possible role of immune cells in the regulation of A-
SMase expression in tumour cells.  
As TAM have been largely shown to be the most abundant leucocytes in melanoma 
lesions and to be able to enhance the aggressiveness of cancer cells (Chen, Huang et al. 
2011; Lin, Zheng et al. 2013), we first analysed their percentage in our tumour models. 
To assess unambiguously the dependence of the observed phenomena by A-SMase, we 
used, as control, tumours derived from a B16 clone (B16-W6_psil10) in which the 
enzyme is stably (Ostrand-Rosenberg, Sinha et al. 2012) silenced during the whole 
tumour progression as described in Bizzozero et al., 2013 (Bizzozero, Cazzato et al. 
2013). 
We observed that, despite changes in A-SMase levels, TAM (CD11b/F4/80 positive cells) 
infiltration is almost the same in B16-F1-derived tumours at early and late stage of 
progression as well as in B16-W6_psil10-derived ones (Figure 3B).  
The fact that TAM presence seemed not to be affected by A-SMase levels during tumour 
progression indicated that their recruitment is independent by A-SMase expression and 




Figure 3: TAM infiltration is not affected by A-SMase levels during tumour progression in 
vivo 
Flow cytometric analysis of tumour-infiltrating immune cells: tumour cell suspensions from different 
tumours were stained with anti-CD11b and anti-F4/80. Representative dot plot of gated CD11b+ cells is 
shown (A). Graphs represent the percentage of F4/80+ cells gated on CD11b+ cells (B). Values are 
expressed as mean ± SEM (n=7 - 13).  
 
To confirm our hypothesis, we carried out an in vitro experiments in which M2 bone 
marrow derived macrophages, the phenotype more similar to the one of TAM (Galdiero, 
Garlanda et al. 2013), were plated in the upper chamber of a Transwell system, while 
B16-F1 cells were plated in the lower one. After 24 hours of co-colture, macrophage 
swere able to induce a decrease of 53± SEM % of A-SMase mRNA levels. This reduction 
might be dependent by a specific factor released by macrophages since no changes in A-
SMase expression were observed when B16 F1 cells were co-coltured with 3T3 
fibroblasts or H5V endothelial cells (Figure 4).  
These data thus confirm our hypothesis about the modulation of tumoural A-SMase by 
TAM and underline the pro-tumoural role of TAM which modify melanoma cells 
conferring them a more aggressive behaviour.  
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Figure 4: Macrophages derived factors downregulate A-SMase mRNA levels in melanoma 
cells in vitro 
qPCR analysis of A-SMase expression in B16-F1 cells co-coltured for 24 hours with macrophages, 3T3 and 
H5V cells or cultured alone (B16-F1). Values are expressed as fold change over control (B16-F1) (n=6 - 
12). 
Asterisks indicate statistical significance vsB16-F1 coltured alone. ***p < 0.001. 
TAM-induced A-SMase downregulation is dependent on Ap2α transcription factor 
We, next, tried to elucidate the molecular mechanism leading to TAM-induced A-SMase 
downregulation. 
It has been demonstrated that A-SMase expression is under the control of the 
transcription factors Sp1 and Ap2α (Langmann, Buechler et al. 1999). In addition, many 
papers described the down-regulation of Ap2α as a central event in melanoma 
progression (Melnikova, Dobroff et al. 2010; Braeuer, Zigler et al. 2011).  
Starting from these data, we analysed Ap2α mRNA levels in B16-F1 cells after co-colture 
with macrophages or 3T3 fibroblasts or H5V endothelial cells and we observed that Ap2α 
mRNA decrease only in B16-F1 co-coltured with macrophages (Figure 5) suggesting that 
TAM-induced A-SMase downregulation is mediated by Ap2α transcription factor through 
release of a soluble factor. More experiments have to be carried out to reveal which this 





Figure 5: TAM-induced A-SMase downregulation is dependent on Ap2α transcription 
factor 
qPCR analysis of Ap2α expression in B16-F1 cells co-coltured for 24 hours with M2-macrophages, 3T3 
and H5V cells or cultured alone (B16-F1). Values are expressed as fold change over control (B16-F1) (n=4 
- 2). 
Asterisks indicate statistical significance vsB16-F1 coltured alone. *p < 0.05. 
A-SMase downregulation in melanoma cells correlates to increased MDSC 
accumulation 
Taking into account that there is a complex crosstalk between tumour cells and its 
immunological microenvironment (Yu, Kortylewski et al. 2007) and that A-SMase 
downregulation into melanoma cells confers them a more aggressive behaviour 
(Bizzozero, Cazzato et al. 2013), we decided to analyse immune cells infiltration within 
B16-F1 tumours at different stage of progression in order to speculate whether this event 
also has influences on the surrounding microenvironment. As above, even in these set of 
experiments B16-W6_psil10 tumours were used as control.   
We first analysed the presence of MDSCs (CD11b+/Gr1+ cells), which have been shown 
to have a crucial role in generating the highly immunosuppressive microenvironment 
typical of melanoma tumours (Umansky and Sevko 2012). Interestingly we found a 
significant increase in CD11b+/Gr1+ MDSCs infiltrating B16-W6_pSIL10 with respect to 
B16-F1 at early stage of tumour growth (Figure 6, right panel). Moreover, the percentage 
of MDSC cells in B16-F1 late stage tumours, in which A-SMase was downregulated, was 
similar to that of B16-W6_pSIL10 early stage (Figure 6, right panel),. Thus, A-SMase 
downregulation seems to be crucial for MDSC recruitment at the tumour burden and 
might play an important role in favouring tumour immune escape. 
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Figure 6: A-SMase downregulation in melanoma cells correlates to increase MDSCs 
accumulation 
Flow cytometric analysis of tumour-infiltrating immune cells: tumour cell suspensions from different 
tumours were stained with anti-CD11b and anti-Gr1 antibodies. A representative dot plot of gated CD11b+ 
cells is shown (A, left panel) (n = 5 - 14). Graphs represent the percentage of Gr1+ cells gated on CD11b+ 
cells (A, right panel). Values are expressed as mean ± SEM (n=5 - 14). 
Asterisks indicate statistical significance vs B16-F1 early stage tumours. **p< 0.01. 
A-SMase-related MDSC accumulation determines immunosuppression 
MDSCs exert their function through the secretion of immunosuppressive cytokines 
leading to the impairment of DCs and cytotoxic lymphocytes (Rodriguez, Quiceno et al. 
2007; Ostrand-Rosenberg, Sinha et al. 2012; Schiavoni, Gabriele et al. 2013), and to an 
increased recruitment of  regulatory CD4+/CD25+/Foxp3+ T lymphocytes (TREGS) 
(Schlecker, Stojanovic et al. 2012). 
Thus, we decided to analyse these cells in our tumour models. First of all we observed a 
decrease in DCs number in tumour showing a downregulation of A-SMase with respect to 
B16-F1 early stage ones (Figure 7A, right panel). Interestingly, in tumour with 
downregulated A-SMase, DCs are not only diminished, but were also immature and 
anergic as indicated by the reduction of the co-stimulatory markers CD80, CD86 and 
MHC II in B16-F1 late stage and B16-W6_psil10 with respect to B16-F1 early stage 
tumours (Figure 7B and C). 
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Despite we didn’t record any significant variation in the number of CD8+ and CD4+ T 
infiltrating lymphocytes (Figure 8A and B, right panels), we observed higher number of 
TREGS in B16-F1 late stage and B16-W6_psil10-derived tumours (Figure 8C). 
DCs impairment and TREGS recruitment could be due to MDSC as we it correlates with 
their major accumulation in tumours with low A-SMase levels (Figure 6).  
These results suggested that the higher malignancy of low A-SMase-expressing tumours 
depends also on the instauration of an immunosuppressive microenvironment which leads 




Figure 7: A-SMase-dependent MDSC accumulation accounts for DCs impairment 
Flow cytometric analysis of tumour-infiltrating immune cells: tumour cell suspensions from different 
tumours were stained with anti CD11c, anti-CD80, anti-CD86 and anti-MHCII antibodies. A representative 
dot plot of gated CD11c+ cells is shown (A, left panel) (n = 7 - 9). Graphs represent the percentage 
of:CD11c+ cells (A, right panel) on total cells; CD80+/MHCII+ cells (B) gated on CD11c+ cells; 
CD86+/MHCII+ cells (C) gated on CD11c+ cells . Values are expressed as mean ± SEM (n=7 - 29). 
Asterisks in indicate statistical significance vs B16-F1 early stage tumours. * p< 0.05; **p< 0.01. 
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Figure 8: A-SMase-dependent MDSC accumulation accounts for TREGS recruitment 
Flow cytometry analysis of tumour-infiltrating immune cells: tumour cell suspensions from different 
tumours were stained with anti-CD4, anti-CD25 and anti-Foxp3 antibodies. Representative dot plots are 
shown (A, B, left panels) (n = 5 - 25). Graphs represent the percentage of: CD8+ cells (A, right panel) and 
CD4+ cells (B, right panel) on total cells; CD25+/Foxp3+ cells gated on CD4+ cells (C).Values are 
expressed as mean ± SEM (n=5 - 25). 
Asterisks indicate statistical significance vs B16-F1 early stage tumours. * p< 0.05. 
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Restoring A-SMase expression reduces melanoma growth 
From these data and from our previous findings, we can state that the downregulation of 
A-SMase expression confers a double advantage to melanoma cells: on one side they 
acquire a more aggressive phenotype (Bizzozero, Cazzato et al. 2013), on the other they 
become able to create around them an immunosuppressive and pro-tumoural 
microenvironment. Thus, we asked whether restoring A-SMase expression in tumour 
cells could prevent or reduce the rising of these pro-tumoural mechanisms.  
It has already been demonstrated that A-SMase overexpression or the injection of the 
recombinant protein (rhASM) have antineoplastic effects sensitizing subcutaneous mouse 
melanomas to irradiation in vivo (Smith and Schuchman 2008), but the consequences of 
restoring A-SMase levels on tumour growth and on tumour microenvironment haven’t 
been studied yet. 
To do this we generated, starting from B16-F1, a cell line (B16-F1_B1A) in which A-
SMase was stably overexpressed by trasfection with the vector pEF1/myc-His containing 
the A-SMase gene (Figure 2in materials and methods). Of importance, in the selected 
clone the increase of A-SMase mRNA (Figure 2A in materials and methods) levels 
correspond with higher protein expression (Figure 2B in materials and methods) and 
activity (Figure 2C materials and methods) in respect to the control cell line. As control, 
we use B16-F1 cell line (B16-F1_pEF1) stably trasfected with the empty vector. 
C57BL6 mice were injected s.c. with 5 × 104B16-F1_pEF1 and B16-F1_B1A cells and 
we observed that B16-F1_pEF1-derived melanomas grew significantly faster than B16-
F1_B1A-derived ones (Figure 9).  
This result is in line with what we previously observed in tumours in which A-SMase was 
silenced (Bizzozero, Cazzato et al. 2013) and confirms the inverse correlation between A-
SMase expression and tumour growth. Taking that into account together with the results 
regarding tumour infiltration observed in B16-F1 late stage and B16-W6_psil10 tumours, 
we wondered whether the slower growth of A-SMase overexpressing tumours is due also 
to a modification of the immunosuppressive microenvironment. .  
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Figure 9:A-SMase overexpression reduces tumour growth 
C57BL/6 mice (10 animals per group) were injected in the right flank with B16-F1_pEF1 and B16-F1_B1A 
(5 × 104 cells). Tumour growth was monitored by measuring tumour volume (mm3) every 2 days. Values 
are expressed as mean ± SEM. 
Asterisks indicate statistical significance vs B16-F1_pEF1 tumours. **p< 0.01; ***p< 0.001 
Restoring A-SMase expression switches tumour microenvironment from a pro- to an 
anti-tumoural phenotype 
Because B16-F1_pEF1 and B16-F1_B1A tumours displayed different tumour growth 
kinetics, we addressed the immune cell infiltration along tumour progression. Thus, we 
explanted melanomas at two stages of progression, when tumour size was 5×5×3 mm 
(early stage) and 10×10×8 mm (late stage) and we proceeded with the flow cytometric 
analysis of tumour infiltrate.  
We, first, analysed what happens to the immunosuppressive cells MDSC and TREGS, that 
are the one affected by the downregulation of A-SMase into melanoma cells, after 
restoring enzyme expression and we observed that in B16-F1_B1A early stage tumours 
there is a  79± SEM % and a  63± SEM % decrease respectively in the number of MDSCs 
and TREGS with respect to B16-F1_pEF1 ones (Figure 10A and B, lower panels). 
Interestingly, these differences become more significant in the late stage of progression, 
when the percentage of MDSCs and TREGS decreases respectively of 70± SEM % and  
76± SEM % in B16-F1_B1A tumours with respect to B16-F1_pEF1 ones (Figure 10A 
and B, lower panels). 
Then, we addressed the other immune cell populations recruited at the tumour site.  
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Surprisingly, the percentage of TAM, which role is mainly pro-tumoural (Chen, Huang et 
al. 2011; Lin, Zheng et al. 2013) and did not change under A-SMase down-regulation, 
was significantly lower in B16-F1_B1A during tumour progression with respect to B16-
F1_pEF1 ones (Figure 11A, lower panel). Conversely, DCs infiltrate is higher in tumours 
overexpressing A-SMase (Figure 11B, lower panel).Moreover, at early stage, CD4+ and 
CD8+ T lymphocytes were significantly higher in B16-F1_B1A tumours with respect to 
B16-F1_pEF1 ones (Figure 11C and D respectively, lower panels). At late stage, the 
percentages of both CD4+ and CD8+ T slightly decrease, but remain however higher in 
B16-F1_B1A tumours with respect to B16-F1_pEF1 ones (Figure 11C and D 
respectively, lower panels). 
All these data demonstrate that A-SMase overexpression in melanoma cells not only 
reverts the effect on tumour immunosuppression following the naturally occurred down-
regulation of the enzyme during tumour progression, but moreover accounts for an high 
unexpected recruitment of immune cells with an anti-tumoural function in the tumour 
microenvironment.   
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Figure 10: A-SMase overexpression reduces immunosuppression 
Flow cytometric analysis of tumour-infiltrating immune cells: tumour cell suspensions from different 
tumours were stained with anti-CD11b, anti-Gr1, anti-CD4, anti-CD25 and anti-Foxp3. Representative dot 
plots of gated Gr1+ (A, upper panel) and CD25+/Foxp3+ (B, upper panel) cells were shown. Graphs 
represent the percentage of:Gr1+ cells (A, lower panel) gated on CD11b+ cells and CD25+/Foxp3+ cells (B, 
lower panel) gated on CD4+ cells. Values are expressed as mean ± SEM (n=5 - 17). 
Asterisks and cross indicate statistical significance vs B16-F1 early stage and B16-F1 late stage tumours 
respectively. * p< 0.05; ++p < 0.01 
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Figure 11: A-SMase overexpression increases recruitment of anti-tumoural immune cells 
Flow cytometric analysis of tumour-infiltrating immune cells: tumour cell suspensions from different 
tumours were stained with anti-CD11b, anti-F4/80, anti-CD11c, anti-CD8 and anti-CD4. Representative dot 
plots of gated CD11b+/F4/80+ (A, upper panel), CD11c+ (B, upper panel), CD8+ (C, upper panel) and 
CD4+ (D, upper panel) cells were shown. Graphs represent the percentage of:CD11b+/F480+(A, lower 
panel), CD11c+(B, lower panel), CD8+ (C, lower panel) and CD4+ (D, lower panel) on total cells. Values 




Asterisks and cross indicate statistical significance vs B16-F1 early stage and B16-F1 late stage tumours 
respectively. * p< 0.05; **p< 0.01. +p< 0.05; +++p < 0.001. 
 
We did not observe differences in the maturation and activation of DCs in our tumour 
models at both the stages of progression. 
These data showed that overexpression of A-SMase in melanoma cells contribute to the 
creation of an antitumoural tumour microenvironment also by inducing a decrease in 





Due to the pro-apoptotic effects of ceramide, cancer cells have developed multiple 
defense mechanisms to overcome its action, including reducing its production and/or 
enhancing its clearance, or elevating the production of the counteracting pro-survival 
lipid, sphingosine-1-phosphate (S1P). These defense mechanisms also may contribute to 
sphingolipid-mediated drug resistance (Oskouian and Saba 2010; Ponnusamy, Meyers-
Needham et al. 2010). Notably, the levels of ceramide are significantly decreased in 
human colon cancers (Selzner, Bielawska et al. 2001), gliomas (Riboni, Campanella et al. 
2002), and ovarian cancers (Rylova, Somova et al. 1998), and an inverse relationship has 
been found between ceramide levels and glioma stratification into high- and low-grade 
tumours (Riboni, Campanella et al. 2002). Thus, modulation of ceramide by cancer cell 
might be considered one of the mechanism of tumour to escape cell death and restoring 
its level by activating the enzymes of its generation a good strategy of tumour therapy. 
Among these enzymes, A-SMase seems to play a crucial role in cancer physiopathology 
(Schuchman 2007). A-SMase is a phosphodiesterase that catalyzes the hydrolysis of 
membrane sphingomyelin to ceramide and phosphorylcholine. The enzyme plays 
important roles in pathophysiology, as it mediates the action of several apoptogenic 
molecules, cytokines and neurotrophins, regulating neuronal function, immunity and 
infections (Grassme, Jendrossek et al. 2003; Ng and Griffin 2006; Herz, Pardo et al. 
2009). It also contributes significantly to the cytotoxic effects of several anticancer drugs 
such as cisplatin, retinoids, doxorubicin and radiation (Gulbins and Kolesnick 2003; 
Lacour, Hammann et al. 2004; Perrotta, Bizzozero et al. 2007; Zeidan and Hannun 2007).  
In this study we showed that A-SMase levels are decreased in different human and 
murine tumours during their progression suggesting its involvement in malignancy 
development. Of interest, in melanoma and colon tumours we observed similar results 
both in human and mouse. 
In our previous work we demonstrated that, in melanoma, A-SMase decrease favours 
tumour ability to grow, invade and metastasise both in mouse and in human (Bizzozero, 




Here we hypothesise as a possible mechanism of this event the release of  
microenvironmental factors acting on melanoma cells and thus modulating A-SMase 
during tumour growth. Indeed, it has been largely shown that a complex cross-talk exists 
between tumour cells and its immunological microenvironment (Yu, Kortylewski et al. 
2007; Mattei, Schiavoni et al. 2012; Businaro, De Ninno et al. 2013; Schiavoni, Gabriele 
et al. 2013) thus leading immune cells to release cytokines which are able to induce 
molecular changes in tumour cells (Kanterman, Sade-Feldman et al. 2012). Of importance 
for our study, TAM have been largely shown to be the most abundant leucocytes in 
melanoma lesions and to be able to enhance the aggressiveness of cancer cells (Chen, 
Huang et al. 2011; Lin, Zheng et al. 2013), evoking them as possible candidates in the 
regulation of A-SMase expression in tumour cells.  
In support of this hypothesis we reported that TAM percentage seemed not to be affected 
by A-SMase levels during tumour progression indicating that their recruitment is 
independent from A-SMase expression and further suggesting their possible involvement 
in modulating the levels of this enzyme. In agreement with this, we observed that bone 
marrow-derived macrophages induce a significant decrease in A-SMase mRNA in B16-
F1 melanoma cells after 24h of in vitro co-colture. Finding out the soluble factors 
responsible for this reduction and dissecting the pathways responsible of this event could 
lead to the identification of key players to be targeted to restore A-SMase levels in 
tumour cells. 
The regulation of A-SMase expression has been poorly investigated, to date we only 
know that in monocytes, A-SMase promoter is under the control of Sp1 and Ap2α 
transcription factors (Langmann, Buechler et al. 1999). Of interest for our work, many 
papers described the down-regulation of Ap2α as a central event in melanoma 
progression (Melnikova, Dobroff et al. 2010; Braeuer, Zigler et al. 2011). Starting from 
these evidences, we showed that after 24h of co-colture with bone marrow-derived 
macrophages, Ap2α expression decreases in B16-F1 cells correlating with the reduction 
of A-SMase levels. Other experiments in which Ap2α is silenced are required to confirm 
unambiguously the dependence of A-SMase expression on this transcription factor. 
All these data further support the existence of a tight cross-talk between various cell types 
at the tumour site which accounts for A-SMase downregulation in melanoma cells thus 
leading to more aggressive tumours, as shown in our previous work (Bizzozero, Cazzato 
et al. 2013). As tumour microenvironment can be considered the product of a developing 
cross-talk between different cells types, we hypothesized that the molecular changes we 
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observed in tumour cells could, in turn, give pro-tumoural and immunosuppressive 
features to the surrounding microenvironment. In this scenario, our data clearly revealed a 
close correlation between the extent and type of tumour infiltrate and A-SMase levels in-
melanoma, in particular, A-SMase decrease accounts for the establishment of an high 
immunosuppressive and pro-tumoural microenvironment. This is indicated by our 
observation that tumours with low A-SMase levels, B16-F1 at late stage of development 
and B16-F1_psil10 at early stage, displayed high MDSCs infiltration, already known to 
be responsible for the establishment of immunosuppression (Umansky and Sevko 2012). 
Our data are in line with previous findings describing an high immunosuppressive 
microenvironment as typical of melanoma lesions (Meyer, Sevko et al. 2011; Umansky 
and Sevko 2012). 
MDSCs exert their function through the secretion of immunosuppressive cytokines 
leading to the impairment of DCs and cytotoxic lymphocytes (Rodriguez, Quiceno et al. 
2007; Ostrand-Rosenberg, Sinha et al. 2012; Schiavoni, Gabriele et al. 2013), and to an 
increased recruitment of  regulatory CD4+/CD25+/Foxp3+ T lymphocytes (TREGS) 
(Schlecker, Stojanovic et al. 2012). Accordingly, in tumours with downregulated A-
SMase, DCs were not only diminished, but also immature and anergic. Moreover the 
same tumours displayed increased TREGS infiltration. 
We clearly showed that the ability to create this immunosuppression together with the 
acquisition of a more aggressive phenotype (Bizzozero, Cazzato et al. 2013), both depend 
on the naturally occurring A-SMase decrease in melanoma cells during tumour 
progression. 
The broad role of A-SMase in tumour pathogenesis we identified, indicates also that the 
enzyme is at the crossroad of key pathways in tumourigenesis. This aspects has clear 
potential in therapeutic perspective in which A-SMase overexpression or administration 
might be consider as an useful adjuvant for cancer therapy. 
To date, studies based on the use of A-SMase for tumour treatment, have concentrated 
mainly on its effect in sensitizing tumour cells to chemotherapy (Smith and Schuchman 
2008; Savic, He et al. 2013), but the consequences of restoring A-SMase levels on tumour 
growth and on tumour microenvironment haven’t been studied yet. Here we demonstrated 
for the first time that restoring A-SMase expression in melanoma cells not only reduces 
tumour growth and immunosuppression, but moreover accounts for a high, unexpected 
recruitment of immune cells with an anti-tumoural function in the tumour 




SMase during all their progression display poor homing of MDSCs and TREGS. Moreover 
A-SMase expression accounts for the creation of an inflammatory microenvironment, as 
shown by the decrease in the percentage of TAMs, which role is mainly pro-tumoural 
(Chen, Huang et al. 2011; Lin, Zheng et al. 2013), together with strong recruitment of 
DCs, CD8+ and CD4+ T lymphocytes.  
In conclusion our results demonstrated for the first time the central role of A-SMase 
expressed by melanoma cells in orchestrating the cross-talk with the surrounding 
microenvironment. These interactions are crucial for tumour fate, lying on its rejection or 
progression. Our observation that A-SMase overexpression “educate” tumour 
microenvironment against cancer cells, further encourage the use of this enzyme as an 
adjuvant for cancer therapy. Indeed, the discovery of this new function that A-SMase 
exerts on the tumour immune system, adds to the previously observed one exerted on 
cancer cell death, thus suggesting that the antineoplastic effect of this enzyme occurs 
through more than one mechanisms.  
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